var title_f16_36_16960="Pulmonary LAM PA";
var content_f16_36_16960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior roentgenogram in a 37-year-old woman with pulmonary lymphangioleiomyomatosis shows normal lung volume and difficult to see cystic changes in all lung zones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert S Crausman, MD and Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16960=[""].join("\n");
var outline_f16_36_16960=null;
var title_f16_36_16961="Teacher questionnaire A";
var content_f16_36_16961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Speech and language evaluation teacher questionnaire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 673px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16961=[""].join("\n");
var outline_f16_36_16961=null;
var title_f16_36_16962="Sinuses and OMC external";
var content_f16_36_16962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Location of the paranasal sinuses and ostio-meatal complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic drawing showing location of the frontal, ethmoid, maxillary, and sphenoid sinuses, as well as the ostio-meatal complex (also called the ostio-meatal unit).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16962=[""].join("\n");
var outline_f16_36_16962=null;
var title_f16_36_16963="Triamcinolone (ophthalmic): Pediatric drug information";
var content_f16_36_16963=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamcinolone (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/55/8052?source=see_link\">",
"    see \"Triamcinolone (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/31/19955?source=see_link\">",
"    see \"Triamcinolone (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9606516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Triesence&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10528035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10528089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/55/8052?source=see_link\">",
"      see \"Triamcinolone (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic injection: Intravitreal: Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular disease: Initial: 4 mg as a single dose; additional doses may be given as needed over the course of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Visualization during vitrectomy: 1-4 mg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9606839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, ophthalmic, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triesence&trade;: 40 mg/mL (1 mL) [contains polysorbate 80; not for I.V. use]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9606553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10528090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Not for I.V. use.",
"     </b>",
"     Shake vial well prior to use. Administer under controlled aseptic conditions (eg, sterile gloves, sterile drape, sterile eyelid speculum). Adequate anesthesia and a broad-spectrum bactericidal agent should be administered prior to injection. Inject immediately after withdrawing from vial. If administration is required in the second eye, a new vial should be used. Do not use if agglomerated (clumpy or granular appearance).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10528076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 4&deg;C to 25&deg;C (39&deg;F to 77&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10528010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intravitreal: Treatment of sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids; visualization during vitrectomy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9606494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TAC (occasional abbreviation for triamcinolone) is an error-prone abbreviation (mistaken as tetracaine-adrenaline-cocaine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9606587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Blurred vision, cataract progression, conjunctival hemorrhage, discomfort (transient), endophthalmitis, glaucoma, hypopyon, inflammation, intraocular pressure increase, optic disc vascular disorder, retinal detachment, vitreous floaters, visual acuity decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Exophthalmos",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10528036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triamcinolone or any component; systemic fungal infections; cerebral malaria; serious infections (except septic shock or tuberculous meningitis); idiopathic thrombocytopenia purpura",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10528074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Corticosteroids should not be used in active ocular herpes simplex.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10528073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunosuppression may occur; patients may be more susceptible to infections. Intravitreal injection has been associated with endophthalmitis and visual disturbances. Blindness has been reported following injection into nasal turbinates and intralesional injections into the head. Safety of intraturbinal, subconjunctival, subtenons, or retrobulbar injection has not been demonstrated. Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9606617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9606555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9606556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triamcinolone was shown to be teratogenic in animal reproduction studies. Some studies have shown an association between first trimester corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. The amount of triamcinolone absorbed systemically following ophthalmic administration is not known.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10528091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following injection, monitor for increased intraocular pressure and endophthalmitis; check for perfusion of optic nerve head immediately after injection, tonometry within 30 minutes, biomicroscopy between 2-7 days after injection.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10528077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10528078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Half-life elimination: Biologic: 18-36 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16059 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16963=[""].join("\n");
var outline_f16_36_16963=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606516\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528035\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528089\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606839\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606553\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528090\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528076\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528010\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606494\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606587\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528036\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528074\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528073\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300166\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606617\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606555\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606556\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528091\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528077\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10528078\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5637?source=related_link\">",
"      Triamcinolone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16548?source=related_link\">",
"      Triamcinolone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/56/16260?source=related_link\">",
"      Triamcinolone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/55/8052?source=related_link\">",
"      Triamcinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/31/19955?source=related_link\">",
"      Triamcinolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31768?source=related_link\">",
"      Triamcinolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5910?source=related_link\">",
"      Triamcinolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/11/27831?source=related_link\">",
"      Triamcinolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/30/32229?source=related_link\">",
"      Triamcinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/46/36580?source=related_link\">",
"      Triamcinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/10/14500?source=related_link\">",
"      Triamcinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_36_16964="Quinupristin and dalfopristin: Patient drug information";
var content_f16_36_16964=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Quinupristin and dalfopristin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     see \"Quinupristin and dalfopristin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/11/1205?source=see_link\">",
"     see \"Quinupristin and dalfopristin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synercid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Synercid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11989649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to quinupristin, dalfopristin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699037",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699606",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 7 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11419 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16964=[""].join("\n");
var outline_f16_36_16964=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216636\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216637\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11989649\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015652\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015651\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015656\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015657\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015659\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015654\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015660\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015661\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=related_link\">",
"      Quinupristin and dalfopristin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/11/1205?source=related_link\">",
"      Quinupristin and dalfopristin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_36_16965="Methyclothiazide: Drug information";
var content_f16_36_16965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methyclothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/357?source=see_link\">",
"    see \"Methyclothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Edema:",
"     </b>",
"     Oral: 2.5-10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 2.5-5 mg/day; may add another antihypertensive if 5 mg is not adequate after a trial of 8-12 weeks of therapy",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food or milk. Administer early in day to avoid nocturia. Administer the last dose of multiple doses no later than 6 PM unless instructed otherwise.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension; adjunctive therapy of edema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Enduron may be confused with Empirin, Imuran&reg;, Inderal&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Necrotizing angiitis, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, purpura, rash, Stevens-Johnson syndrome, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte imbalance, hypercalcemia, hyperglycemia, hyperuricemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, epigastric distress, gastric irritation, nausea, pancreatitis, sialadenitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Cramping, muscle spasm, paresthesias, restlessness, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision (transient), xanthopsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pneumonitis, pulmonary edema, respiratory distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methyclothiazide or any component of the formulation, thiazides, or sulfonamide-derived drugs; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with thiazide or sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid in severe renal disease (ineffective). May precipitate azotemia; discontinue or consider withholding if renal impairment occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F194909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid dong quai, St John's wort (may also cause photosensitization). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13374779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Thiazide diuretics cross the placenta and are found in cord blood. Maternal use may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults. Use of thiazide diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13374780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thiazide diuretics are found in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9528871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food or milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F194904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methyclothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $173.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F194895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess weight, I &amp; O reports daily to determine fluid loss; blood pressure; serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F194905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Enduron (AU, GB);",
"     </li>",
"     <li>",
"      Urimor (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water, as well as, potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/36/16965/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9633 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16965=[""].join("\n");
var outline_f16_36_16965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194933\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194916\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194917\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194897\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194882\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803171\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194898\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194940\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194931\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194902\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194886\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299694\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194891\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194909\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194892\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374779\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194921\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374780\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9528871\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194904\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194895\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194905\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194885\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194901\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9633\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9633|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/357?source=related_link\">",
"      Methyclothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_36_16966="Trapezoid edema T1 MRI";
var content_f16_36_16966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51063%7EEM%2F59798%7EEM%2F72554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51063%7EEM%2F59798%7EEM%2F72554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trapezoid edema on T1 MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This T1-weighted, axial magnetic resonance image of the wrist shows decreased signal intensity throughout the trapezoid, when compared to the strength of the signal from the trapezium (Tm), capitate (C), and hamate (H) bones. This suggests the presence of edema consistent with microtrabecular injury. The trapezoid is the dark-appearing bone between the trapezium and capitate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trapezoid edema with T2 axial MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This T2-weighted, axial magnetic resonance image of the wrist shows increased signal in the trapezoid compared to the marrow signal from the adjacent bones. This appearance of the trapezoid showing edema consistent with microtrabecular injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trapezoid edema on T2 coronal MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This T2-weighted, coronal magnetic resonance image of the wrist shows increased signal in the trapezoid, when compared to the adjacent trapezium (T) and capitate (C). This appearance is consistent with edema due to microtrabecular injury to the trapezoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16966=[""].join("\n");
var outline_f16_36_16966=null;
var title_f16_36_16967="CD68 cells in muscle granuloma in sarcoidosis";
var content_f16_36_16967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    CD68 cells in muscle granuloma in sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CD68+ cells that may be macrophages within a muscle granuloma in sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven A Greenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16967=[""].join("\n");
var outline_f16_36_16967=null;
var title_f16_36_16968="Role of bronchoalveolar lavage in diagnosis of interstitial lung disease";
var content_f16_36_16968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16968/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16968/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16968/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16968/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16968/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16968/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/36/16968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage (BAL) is a minimally invasive procedure performed during flexible fiberoptic bronchoscopy to obtain a sample of alveolar cells. Analysis of BAL cell counts, cytology, and culture provides insights into immunologic, inflammatory, neoplastic, and infectious processes occurring at the alveolar level.",
"   </p>",
"   <p>",
"    This topic will review the role of BAL in the setting of interstitial lung disease (ILD) and the cell profiles found in common interstitial lung diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The technique of BAL and the analysis of lavage fluid are discussed separately, as is the overall approach to the patient with ILD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONSTITUENTS OF BAL IN ILD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the evaluation of interstitial lung disease, BAL findings are typically nonspecific, being consistent with or suggestive of a given condition, rather than pathognomonic. In patients with an acute presentation of dyspnea and interstitial opacities, BAL is sometimes helpful to identify alveolar hemorrhage, malignancy, or opportunistic infection (",
"    <a class=\"graphic graphic_table graphicRef55231 \" href=\"UTD.htm?24/0/24588\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When BAL fluid is obtained from healthy adults, only small numbers of lymphocytes, neutrophils, and eosinophils accompany the predominant population of alveolar macrophages (",
"    <a class=\"graphic graphic_table graphicRef50382 graphicRef71367 graphicRef66165 \" href=\"UTD.htm?1/56/1920\">",
"     table 2A-C",
"    </a>",
"    ). In patients with ILD, a variety of changes in the relative and absolute numbers of individual cell constituents have been described. Usually, these changes are nonspecific, but occasionally, the pattern is sufficiently characteristic to guide the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef54377 \" href=\"UTD.htm?1/3/1085\">",
"     table 3",
"    </a>",
"    ), or rarely, to confirm the diagnosis of a particular ILD (",
"    <a class=\"graphic graphic_table graphicRef55231 \" href=\"UTD.htm?24/0/24588\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphocytosis (usually greater than 30 percent of the total white cells) (",
"      <a class=\"graphic graphic_table graphicRef69908 \" href=\"UTD.htm?3/47/3835\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The ratio of CD4 positive to CD8 positive lymphocytes",
"      <span class=\"nowrap\">",
"       (CD4/CD8)",
"      </span>",
"      may permit further narrowing of the possible diagnoses (",
"      <a class=\"graphic graphic_table graphicRef63294 \" href=\"UTD.htm?41/19/42299\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/3,6\">",
"       3,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Eosinophilic (usually greater than 5 percent of the white cells) (",
"      <a class=\"graphic graphic_table graphicRef64886 \" href=\"UTD.htm?15/50/16171\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Malignant cells (eg, metastatic carcinoma, Reed-Sternberg cells, monoclonal B lymphocytes) (",
"      <a class=\"graphic graphic_table graphicRef55231 \" href=\"UTD.htm?24/0/24588\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LYMPHOCYTIC BAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypersensitivity pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAL, especially when combined with transbronchial biopsy, is a sensitive tool for detecting an alveolitis in patients suspected of hypersensitivity pneumonitis (HP) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/7\">",
"     7",
"    </a>",
"    ]. A marked lymphocytosis (often exceeding 50 percent of the cells recovered) is a nonspecific but helpful finding, since this level of lymphocytosis is uncommon in diseases often considered in the differential diagnosis. The",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio is usually decreased (&lt;1.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=see_link\">",
"     \"Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=see_link\">",
"     \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased number of mast cells (&gt;1 percent) may be noted, although this is not generally used clinically. The presence of mast cells may also be helpful in monitoring for ongoing exposure to the responsible antigen, as mast cells are usually increased following acute exposure and decline toward normal within one to three months after removal of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of sarcoidosis cannot be established on the basis of BAL findings alone. However, certain patterns on BAL can help to narrow the differential diagnosis. Criteria for the diagnosis of sarcoidosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the majority of patients with sarcoidosis, the BAL lymphocyte count and percentage are increased, while the neutrophil and eosinophil percentages are normal (",
"    <a class=\"graphic graphic_table graphicRef54377 \" href=\"UTD.htm?1/3/1085\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. In addition, a predominance of T-lymphocytes with an elevated",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio is a frequent finding (",
"    <a class=\"graphic graphic_table graphicRef63294 \" href=\"UTD.htm?41/19/42299\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/3,9-11\">",
"     3,9-11",
"    </a>",
"    ]. The duration of disease and the clinical variables (eg, the presence of extrapulmonary disease) appear to affect the cellular patterns in the recovered fluid, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Early\" or active sarcoidosis is characterized by increases in the total numbers of cells recovered, the number of lymphocytes (\"high intensity alveolitis\"), and the",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      T-lymphocyte ratio (&gt;2:1) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Late\" or advanced sarcoidosis is characterized by a relative increase in CD8 T-lymphocytes and neutrophils (to greater than 3 percent of the total). Significant numbers of mast cells in BAL fluid (&gt;1 percent), particularly in combination with BAL lymphocytosis or neutrophilia, are associated with advanced or progressive sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single BAL that shows a normal",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      T-lymphocyte ratio may predict a good prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serial lavage analysis may be more helpful in defining the disease course than a single BAL analysis early in the course of the disease, although it does not add substantially to the information obtained from serial pulmonary function tests. In the subset of patients with persistent BAL lymphocytosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a persistently elevated",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      T-lymphocyte ratio, declines in lung function are more likely, particularly in untreated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/13-18\">",
"       13-18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MIXED CELLULARITY BAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a number of interstitial lung diseases, more than one type of cell may be increased in the BAL, or the proportions may vary over the course of the disease (",
"    <a class=\"graphic graphic_table graphicRef54377 \" href=\"UTD.htm?1/3/1085\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69908 \" href=\"UTD.htm?3/47/3835\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76619 \" href=\"UTD.htm?7/23/7547\">",
"     table 7",
"    </a>",
"    ). For these ILDs, even when a particular pattern is more common, the BAL results are not diagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Idiopathic pulmonary fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial pneumonia limited to the lung and associated with the histologic appearance of usual interstitial pneumonia (UIP). BAL has a limited role in the diagnosis and management of IPF, as the diagnosis usually depends on the results of a high resolution computed tomography (HRCT) scan and lung biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with IPF, BAL cell counts usually show a several-fold increase in the total number of inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/19-25\">",
"     19-25",
"    </a>",
"    ]. However, the percentages of various cell types found in the lavage fluid do not correlate with clinical parameters, or pulmonary function studies. The main value of BAL in these patients is to exclude other processes. Nevertheless, some cell count patterns have been noted and may be helpful. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with suspected IPF, a BAL lymphocyte count less than 30 percent is consistent with IPF, whereas a higher percentage may suggest an alternate diagnosis. As an example, among 74 patients with IPF suggested by the clinical presentation and HRCT scanning, the only patients who were determined to have a non-IPF diagnosis (eg, hypersensitivity pneumonitis, nonspecific interstitial pneumonia) had a BAL lymphocytosis of 30 percent or greater [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conflicting results have been reported regarding the significance of BAL neutrophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. In the largest series of 156 patients with biopsy proven IPF, each doubling of baseline BAL fluid neutrophil percentage was associated with a 30 percent increase in risk of mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/28\">",
"       28",
"      </a>",
"      ]. In a separate study of 81 IPF patients, BAL fluid neutrophil and lymphocyte counts predicted mortality in current smokers, but not among never smokers or former smokers in an adjusted analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased BAL fluid lymphocyte and eosinophil percentages have been variably associated with increased mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The value of serial BAL is unclear, due to the absence of large, well-characterized study populations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonspecific interstitial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case series have noted a lymphocytic BAL in patients with nonspecific interstitial pneumonia (NSIP), although others have not found this. It is possible that this reflects varying proportions of patients with cellular versus fibrotic NSIP. In a study that compared BAL cell counts from 35 patients with IPF and 19 with fibrotic NSIP, no significant difference was noted in the numbers or relative proportions of cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=see_link\">",
"     \"Nonspecific interstitial pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cryptogenic organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consistent, though nonspecific, BAL findings in cryptogenic organizing pneumonitis (COP) include an increased total numbers of cells and often a \"mixed pattern\" characterized by increases in the total number of macrophages, lymphocytes, neutrophils, and eosinophils. The",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio is usually decreased. These findings are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H9#H9\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAL appears to have a limited value in the diagnosis, assessment, and monitoring of connective tissue diseases affecting the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/3,29\">",
"     3,29",
"    </a>",
"    ]. However, BAL may be valuable in clarifying other pulmonary problems which may develop in this setting, including drug-induced pulmonary disease, infection, pulmonary hemorrhage, alveolar proteinosis, and malignancy.",
"   </p>",
"   <p>",
"    The typical BAL cell counts reported in various connective tissue diseases with and without concomitant ILD are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef73147 \" href=\"UTD.htm?35/44/36555\">",
"     table 8",
"    </a>",
"    ). These findings are discussed further under the individual topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Drug-induced pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs have been associated with interstitial lung disease. Examples include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    , chemotherapeutic agents, and cocaine (see appropriate topic reviews). Often the diagnosis is not suspected or is difficult to confirm. BAL may be of value in suggesting the presence of drug-related lung injury, or in ruling out other problems (eg, infection or recurrent malignancy) that are common when chemotherapeutic agents are used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/30\">",
"     30",
"    </a>",
"    ]. The patterns of BAL findings suggestive of drug-related lung disease are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef52198 \" href=\"UTD.htm?24/60/25548\">",
"     table 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EOSINOPHILIC BAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A marked increase in the BAL eosinophil count (&ge;30 percent) is typically a manifestation of idiopathic acute eosinophilic pneumonia, chronic eosinophilic pneumonia (CEP), or tropical pulmonary eosinophilia. More modest increases in BAL eosinophils (&lt;30 percent) may be seen in IPF, sarcoidosis, pulmonary Langerhans cell histiocytosis, drug-induced pneumonitis, coccidioidal infection, and connective tissue diseases affecting the lungs (",
"    <a class=\"graphic graphic_table graphicRef64886 \" href=\"UTD.htm?15/50/16171\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=see_link\">",
"     \"Tropical filarial pulmonary eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute eosinophilic pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic acute eosinophilic pneumonia is an acute febrile pneumonitis of less than one week duration with marked eosinophil accumulation in the lungs. At the onset, the chest radiograph may show only subtle reticular or hazy opacities, often with Kerley B lines. However, most patients present with or develop diffuse, mixed alveolar and reticular opacities. BAL eosinophil counts are typically over 25 percent. The differential diagnosis includes drug-induced pneumonitis, tropical pulmonary eosinophilia, fungal infection, and Churg-Strauss syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link\">",
"     \"Idiopathic acute eosinophilic pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic eosinophilic pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic eosinophilic pneumonia (CEP) is a disorder characterized by an indolent onset of dyspnea and a chest radiograph with bilateral peripheral opacities described as the \"photographic negative\" of pulmonary edema. In a patient with a compatible clinical presentation, a BAL eosinophil count greater than 40 percent is strongly suggestive of CEP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of pulmonary eosinophilia\", section on 'Chronic eosinophilic pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Eosinophilia and infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAL eosinophilia may also be seen in patients with Coccidioidomycosis infection and tropical filarial pulmonary eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The presentation and diagnosis of these diseases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=see_link\">",
"     \"Tropical filarial pulmonary eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HEMORRHAGIC BAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse pulmonary hemorrhage occurs in a variety of conditions and is frequently a life-threatening event. Patients usually report dyspnea, but hemoptysis is variable. The chest radiograph usually shows new patchy or diffuse alveolar opacities, although recurrent episodes may result in interstitial opacities. Frankly bloody or blood-tinged BAL fluid suggests this diagnosis, particularly when the amount of blood in the effluent increases over three successive lavages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link&amp;anchor=H12#H12\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional cytologic findings include the demonstration of hemophagocytosis by alveolar macrophages or the presence of hemosiderin-laden macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/3,33-35\">",
"     3,33-35",
"    </a>",
"    ]. The latter appear approximately 48 hours following the onset of pulmonary hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/36\">",
"     36",
"    </a>",
"    ]. A hemosiderin scoring system has been developed based upon the colorimetric intensity of Prussian blue-stained alveolar macrophages. The score by this system correlates with the degree of pulmonary hemorrhage on histologic sections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Scores greater than 100 connote significant hemorrhage, while normal subjects have scores that range from 4 to 25 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the diagnosis of pulmonary hemorrhage is confirmed, then the specific cause of the process must be sought [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/34,40\">",
"     34,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER USEFUL BAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to changes in the number and proportion of cells, other findings in the BAL may be helpful. Some of these are described below and include the presence of lipid-laden macrophages, malignant cells, mineral dust, and an increase in the number of CD1 positive Langerhans cells. The presence of alveolar macrophages with large, lamellated inclusion bodies is consistent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    use, but not necessarily indicative of amiodarone toxicity. (",
"    <a class=\"graphic graphic_table graphicRef52198 \" href=\"UTD.htm?24/60/25548\">",
"     table 9",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Drug-induced pulmonary disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chronic microaspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux with aspiration is frequently considered in the differential diagnosis of recurrent pneumonia or atypical, diffuse interstitial opacities. When chronic aspiration is suspected, BAL should be performed in the area of greatest radiographic abnormality (usually the dependent lung zones).",
"   </p>",
"   <p>",
"    BAL cellularity is increased and the differential reveals increases in lymphocytes, eosinophils, and macrophages. The most important diagnostic finding is the presence of large numbers of lipid-laden macrophages, which is suggestive of chronic aspiration or lipoid pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/41\">",
"     41",
"    </a>",
"    ]. Marked vacuolization of the alveolar macrophages is appreciated on routine modified Wright's staining; fat staining with oil-red-O or Sudan black demonstrates the lipid nature of the vacuoles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/41\">",
"     41",
"    </a>",
"    ]. Multinucleated giant cells may be recovered by BAL and frequently contain lipid droplets within their cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Malignant cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancies such as lymphangitic carcinomatosis and pulmonary lymphoma can sometimes present with diffuse interstitial opacities and be diagnosed by BAL [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/46\">",
"     46",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of patients with lymphangitic breast cancer, the BAL cytology revealed metastatic tumor in 10 of the 14 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reed-Sternberg cells were identified in the BAL from 6 of 50 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with primary pulmonary lymphoma, lymphocytic alveolitis (&gt;20 percent lymphocytes) is suggestive. Flow cytometry of BAL fluid can then be used to identify a clonal B-cell population with Ig gene clonal rearrangements [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pneumoconioses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of occupational lung disease rarely requires tissue biopsy or BAL. However, BAL can sometimes demonstrate respiratory tract deposition and retention of mineral dusts. The amount of mineral dust recovered appears to bear some relationship to the severity of the exposure, but considerable overlap occurs among asymptomatic, exposed workers and those with clinical disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link\">",
"     \"Asbestosis\"",
"    </a>",
"    .) Thus, BAL findings in individual patients must be considered with caution.",
"   </p>",
"   <p>",
"    The potential usefulness of antigen-specific lymphocyte transformation tests (eg, beryllium) in the diagnosis of specific occupational lung diseases is under investigation. The beryllium lymphocyte proliferation test performed on peripheral blood or BAL fluid has become the standard industry surveillance tool for identifying beryllium-exposed workers who are beryllium-sensitized or in the early stages of chronic beryllium disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22234?source=see_link\">",
"     \"Chronic beryllium disease (berylliosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pulmonary Langerhans cell histiocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic finding in BAL from patients with pulmonary Langerhans cell histiocytosis is an increase in CD1 positive Langerhans cells to greater than 5 percent of total cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16968/abstract/35\">",
"     35",
"    </a>",
"    ]. However, this finding has a low sensitivity and is only found in half of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link&amp;anchor=H13#H13\">",
"     \"Pulmonary Langerhans cell histiocytosis\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchoalveolar lavage (BAL) is a minimally invasive procedure performed during flexible fiberoptic bronchoscopy to obtain a sample of alveolar cells. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in the relative and absolute numbers of cells in BAL fluid have been described in a variety of interstitial lung diseases (ILD). Usually, these changes are nonspecific, but occasionally they are sufficiently characteristic to narrow the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef54377 \" href=\"UTD.htm?1/3/1085\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Constituents of BAL in ILD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In sarcoidosis lung disease, the BAL lymphocyte count and percentage are increased, while the neutrophil and eosinophil percentages are normal (",
"      <a class=\"graphic graphic_table graphicRef54377 \" href=\"UTD.htm?1/3/1085\">",
"       table 3",
"      </a>",
"      ). The",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      T-lymphocyte ratio (&gt;2) is typically increased in early, active disease, but may be lower in more advanced disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Sarcoidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In hypersensitivity pneumonitis, BAL typically shows a marked lymphocytosis (often exceeding 50 percent of the cells recovered), which is uncommon in diseases often considered in the differential diagnosis. The",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratio is usually decreased (&lt;1). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hypersensitivity pneumonitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of ILDs have nonspecific and variable increases in the BAL cell constituents, including idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, connective tissue disease-related ILD, and drug-induced ILD. In these diseases, the role of BAL is largely to exclude other processes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mixed cellularity BAL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main causes of BAL eosinophilia (&gt;25 percent eosinophils) are idiopathic acute eosinophilic pneumonia, chronic eosinophilic pneumonia, and infection (eg, fungal and parasitic). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Eosinophilic BAL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with ILD and a compatible clinical presentation, BAL fluid should be examined for the presence of hemosiderin or lipid-laden macrophages, Langerhans cells, and malignant cells that would indicate alveolar hemorrhage, lipoid pneumonia, pulmonary Langerhans histiocytosis, or neoplastic disease, respectively. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Other useful BAL findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/1\">",
"      Kilin&ccedil; G, Kolsuk EA. The role of bronchoalveolar lavage in diffuse parenchymal lung diseases. Curr Opin Pulm Med 2005; 11:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/2\">",
"      Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/3\">",
"      Welker L, J&ouml;rres RA, Costabel U, Magnussen H. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004; 24:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/4\">",
"      Meyer KC. The role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med 2004; 25:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/5\">",
"      Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/6\">",
"      Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/7\">",
"      Lynch DA, Rose CS, Way D, King TE Jr. Hypersensitivity pneumonitis: sensitivity of high-resolution CT in a population-based study. AJR Am J Roentgenol 1992; 159:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/8\">",
"      Semenzato G, Bjermer L, Costabel U, et al. Clinical guidelines and indications for bronchoalveolar lavage (BAL): extrinsic allergic alveolitis. Eur Respir J 1990; 3:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/9\">",
"      Drent M, Mansour K, Linssen C. Bronchoalveolar lavage in sarcoidosis. Semin Respir Crit Care Med 2007; 28:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/10\">",
"      Winterbauer RH, Lammert J, Selland M, et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/11\">",
"      Danila E, Norkniene J, Jurgauskiene L, Malickaite R. Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis. Clin Respir J 2009; 3:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/12\">",
"      Poulter LW, Rossi GA, Bjermer L, et al. The value of bronchoalveolar lavage in the diagnosis and prognosis of sarcoidosis. Eur Respir J 1990; 3:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/13\">",
"      Costabel U, Bross KJ, Guzman J, et al. Predictive value of bronchoalveolar T cell subsets for the course of pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/14\">",
"      Verstraeten A, Demedts M, Verwilghen J, et al. Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis. Chest 1990; 98:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/15\">",
"      Bjermer L, Rosenhall L, Angstr&ouml;m T, H&auml;llgren R. Predictive value of bronchoalveolar lavage cell analysis in sarcoidosis. Thorax 1988; 43:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/16\">",
"      Okada M, Takahashi H, Nukiwa T, et al. Correlative analysis of longitudinal changes in bronchoalveolar lavage, 67gallium scanning, serum angiotensin-converting enzyme activity, chest X-ray, and pulmonary function tests in pulmonary sarcoidosis. Jpn J Med 1987; 26:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/17\">",
"      Israel-Biet D, Venet A, Chr&eacute;tien J. Persistent high alveolar lymphocytosis as a predictive criterion of chronic pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/18\">",
"      Ceuppens JL, Lacquet LM, Mari&euml;n G, et al. Alveolar T-cell subsets in pulmonary sarcoidosis. Correlation with disease activity and effect of steroid treatment. Am Rev Respir Dis 1984; 129:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/19\">",
"      Watters LC, Schwarz MI, Cherniack RM, et al. Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/20\">",
"      Haslam PL, Turton CW, Heard B, et al. Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax 1980; 35:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/21\">",
"      Haslam PL, Turton CW, Lukoszek A, et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/22\">",
"      Turner-Warwick M, Haslam PL. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/23\">",
"      Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/24\">",
"      Merrill WW, Reynolds HY. Bronchial lavage in inflammatory lung disease. Clin Chest Med 1983; 4:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/25\">",
"      Fireman E, Vardinon N, Burke M, et al. Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis. Eur Respir J 1998; 11:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/26\">",
"      Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003; 22:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/27\">",
"      Tabuena RP, Nagai S, Tsutsumi T, et al. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese Patients. Respiration 2005; 72:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/28\">",
"      Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/29\">",
"      Wallaert B, Rossi GA, Sibille Y. Clinical guidelines and indications for bronchoalveolar lavage (BAL): collagen-vascular diseases. Eur Respir J 1990; 3:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/30\">",
"      Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/31\">",
"      Swartz J, Stoller JK. Acute eosinophilic pneumonia complicating Coccidioides immitis pneumonia: a case report and literature review. Respiration 2009; 77:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/32\">",
"      Ong RK, Doyle RL. Tropical pulmonary eosinophilia. Chest 1998; 113:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/33\">",
"      Kindt GC, Weiland JE, Davis WB, et al. Bronchiolitis in adults. A reversible cause of airway obstruction associated with airway neutrophils and neutrophil products. Am Rev Respir Dis 1989; 140:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/34\">",
"      Grebski E, Hess T, Hold G, et al. Diagnostic value of hemosiderin-containing macrophages in bronchoalveolar lavage. Chest 1992; 102:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/35\">",
"      Costabel U, Guzman J, Bonella F, Oshimo S. Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med 2007; 28:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/36\">",
"      Sherman JM, Winnie G, Thomassen MJ, et al. Time course of hemosiderin production and clearance by human pulmonary macrophages. Chest 1984; 86:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/37\">",
"      Golde DW, Drew WL, Klein HZ, et al. Occult pulmonary haemorrhage in leukaemia. Br Med J 1975; 2:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/38\">",
"      Drew WL, Finley TN, Golde DW. Diagnostic lavage and occult pulmonary hemorrhage in thrombocytopenic immunocompromised patients. Am Rev Respir Dis 1977; 116:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/39\">",
"      Kahn FW, Jones JM, England DM. Diagnosis of pulmonary hemorrhage in the immunocompromised host. Am Rev Respir Dis 1987; 136:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/40\">",
"      Costabel U, Guzman J. Bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulm Med 2001; 7:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/41\">",
"      Corwin RW, Irwin RS. The lipid-laden alveolar macrophage as a marker of aspiration in parenchymal lung disease. Am Rev Respir Dis 1985; 132:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/42\">",
"      Lauque D, Dongay G, Levade T, et al. Bronchoalveolar lavage in liquid paraffin pneumonitis. Chest 1990; 98:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/43\">",
"      Silverman JF, Turner RC, West RL, Dillard TA. Bronchoalveolar lavage in the diagnosis of lipoid pneumonia. Diagn Cytopathol 1989; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/44\">",
"      Spatafora M, Bellia V, Ferrara G, Genova G. Diagnosis of a case of lipoid pneumonia by bronchoalveolar lavage. Respiration 1987; 52:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/45\">",
"      Pujol JL, Barn&eacute;on G, Bousquet J, et al. Interstitial pulmonary disease induced by occupational exposure to paraffin. Chest 1990; 97:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/46\">",
"      Rennard SI. Bronchoalveolar lavage in the diagnosis of cancer. Lung 1990; 168 Suppl:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/47\">",
"      Lower EE, Baughman RP. Pulmonary lymphangitic metastasis from breast cancer. Lymphocytic alveolitis is associated with favorable prognosis. Chest 1992; 102:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16968/abstract/48\">",
"      Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J 2002; 20:750.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4308 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-7C4F869326-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16968=[""].join("\n");
var outline_f16_36_16968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONSTITUENTS OF BAL IN ILD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LYMPHOCYTIC BAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypersensitivity pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MIXED CELLULARITY BAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drug-induced pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EOSINOPHILIC BAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Eosinophilia and infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HEMORRHAGIC BAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER USEFUL BAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chronic microaspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Malignant cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pneumoconioses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4308\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4308|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/0/24588\" title=\"table 1\">",
"      Diagnostic value of BAL in ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/4/30797\" title=\"table 2A\">",
"      BAL fluid in non smokers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/20/31053\" title=\"table 2B\">",
"      BAL fluid in former smokers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/63/30717\" title=\"table 2C\">",
"      BAL fluid in smokers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/3/1085\" title=\"table 3\">",
"      Cellular patterns in BAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/47/3835\" title=\"table 4\">",
"      ILD with BAL lymphocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/19/42299\" title=\"table 5\">",
"      T lymphocyte ratios in disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/50/16171\" title=\"table 6\">",
"      ILD associated BAL eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/23/7547\" title=\"table 7\">",
"      ILD associated BAL neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/44/36555\" title=\"table 8\">",
"      BAL connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/60/25548\" title=\"table 9\">",
"      BAL drug induced lung disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=related_link\">",
"      Asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22234?source=related_link\">",
"      Chronic beryllium disease (berylliosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=related_link\">",
"      Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=related_link\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=related_link\">",
"      Tropical filarial pulmonary eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_36_16969="Initial approach to low-risk clinically localized prostate cancer";
var content_f16_36_16969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial approach to low-risk clinically localized prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16969/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16969/contributors\">",
"     Eric A Klein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16969/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16969/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16969/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16969/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16969/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/36/16969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most prostate cancers now are diagnosed while clinically localized, based in part upon the widespread use of serum prostate specific antigen (PSA) measurement. Many of these cancers are biologically indolent and may never become clinically evident. As such, treatment needs to take into account the natural history of the disease and the risk of progression.",
"   </p>",
"   <p>",
"    For patients diagnosed with prostate cancer confined to the prostate, standard management options include radical prostatectomy, radiation therapy (external beam, brachytherapy), and, for carefully selected patients with very low or low risk disease, active surveillance. When disease extends through the prostatic capsule, into the seminal vesicles, or into regional lymph nodes, radical prostatectomy may be combined with adjuvant radiation therapy (RT). In addition, definitive local therapy, particularly RT, may be supplemented with androgen deprivation therapy (ADT) for men at high risk of disseminated disease.",
"   </p>",
"   <p>",
"    Key factors in choosing treatment for an individual patient include the likelihood of recurrence or metastasis following treatment (risk stratification), the patient's age and life expectancy, the presence or absence of significant comorbidity, and patient preferences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link&amp;anchor=H11494930#H11494930\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic discusses the initial management approach for men with low-risk prostate cancer. The approach to treatment of men with intermediate and high-risk prostate cancer, locally advanced (very high risk) disease, and stage IV disease (clinical lymph node involvement or disseminated metastases) are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"       \"Overview of the treatment of disseminated prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11496394\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of men with newly diagnosed prostate cancer needs to incorporate a consideration of the prolonged natural history of prostate cancer and the risk for progression to disseminated, potentially fatal disease.",
"   </p>",
"   <p>",
"    Risk stratification uses the clinical stage of disease, baseline serum prostate specific antigen (PSA), the Gleason score, and the extent of prostate involvement (including the number of biopsy cores containing cancer) to divide patients into prognostic categories (",
"    <a class=\"graphic graphic_table graphicRef75565 graphicRef67222 \" href=\"UTD.htm?38/23/39294\">",
"     table 1A-B",
"    </a>",
"    ). Although there are fairly arbitrary boundaries between these prognostic categories, prostate cancer is a broad continuum. Risk stratification is combined with patient age, overall medical condition, the presence or absence of symptoms, and patient preferences in guiding initial therapy decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with very low risk clinically localized prostate cancer have disease detected by prostate biopsy only, without detectable abnormality on digital rectal examination or imaging. To be classified as very low risk, such patients must have a Gleason score of 6 or less on biopsy and a serum PSA &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      Furthermore, the extent of disease within the prostate must be limited (ie, fewer than three positive biopsy cores with less than 50 percent involvement in any one core, and a PSA density less than 0.15",
"      <span class=\"nowrap\">",
"       ng/mL/gram)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low-risk prostate cancer &ndash; Patients with low-risk, clinically localized prostate cancer either have disease limited to one lobe of the prostate (T2a) or no apparent tumor (T1, diagnosis based upon a biopsy only, with no abnormal findings on imaging or palpation), a serum PSA &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and a Gleason score &le;6.",
"     </li>",
"     <li>",
"      Intermediate-risk prostate cancer &ndash; Men with intermediate-risk clinically localized prostate cancer can have more extensive tumor in the prostate (ie, involving more than one-half of one lobe of the prostate [T2b] or with bilateral disease [T2c] on initial examination or imaging), but without extracapsular extension or seminal vesicle involvement. In addition, patients with clinical stage T1 or T2a disease are classified as having intermediate risk disease based upon a serum PSA between 10 and 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or a Gleason score 7 on biopsy.",
"     </li>",
"     <li>",
"      High-risk prostate cancer &ndash; Patients with high-risk, clinically localized prostate cancer may have more extensive disease, based upon the presence of extracapsular extension (T3a). In addition, some patients with less extensive disease are classified as being at high risk because of a serum PSA &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or a Gleason score of 8 to 10.",
"     </li>",
"     <li>",
"      Very high risk prostate cancer &ndash; Patients whose initial evaluation suggests locally advanced disease (T3b or T4) diagnosed based upon clinical staging but without lymph node involvement (N0) or distant metastases (M0) are at very high risk of local recurrence or distant metastases.",
"     </li>",
"     <li>",
"      Patients with lymph node involvement or disseminated metastases are classified as having stage IV disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial approaches to treatment for men with very low or low-risk prostate cancer are discussed here. The initial management approaches to patients with intermediate or high risk prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833689\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative advantages and disadvantages of different treatment approaches for men with newly diagnosed low risk and very low risk prostate cancer are discussed in this section. Standard treatment approaches include active surveillance in selected cases, radical prostatectomy, external beam RT, and brachytherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833697\">",
"    <span class=\"h2\">",
"     Active surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active surveillance is defined as the postponement of immediate definitive therapy, with curative-intent treatment instituted if there is clinical evidence of disease progression. Active surveillance is an appropriate treatment option for some patients with prostate cancers that are small, have a low Gleason grade, and thus are thought to have a relatively low risk of progression (TNM anatomic prognostic group I (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 1B",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    The goal of active surveillance is to avoid treatment-related complications for men whose cancers are not likely to progress. For many men, such disease either never requires treatment or treatment can be postponed for a prolonged period without significantly decreasing the chance of cure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=see_link&amp;anchor=H2#H2\">",
"     \"Active surveillance for men with early prostate cancer\", section on 'Rationale'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Active surveillance must be distinguished from \"watchful waiting\", which is based upon the premise that some men will not benefit from definitive treatment of their localized prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/2\">",
"     2",
"    </a>",
"    ]. For patients managed with watchful waiting, the decision is made at the outset that the patient is not a candidate for definitive therapy and to provide palliative treatment (typically androgen deprivation therapy, ADT) if and when symptomatic progression requires therapy. Watchful waiting may be an acceptable alternative for men with short life expectancy based upon age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substantial comorbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/55/24441?source=see_link\">",
"     \"Prostate cancer in elderly patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H167060109#H167060109\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Survival impact of radical prostatectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no results from randomized clinical trials that have compared immediate definitive treatment (radical prostatectomy or RT) with active surveillance (ie, deferred definitive therapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=see_link&amp;anchor=H9#H9\">",
"     \"Active surveillance for men with early prostate cancer\", section on 'Randomized trials of active surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the potential for side effects associated with aggressive treatment of indolent disease, active surveillance is an option for patients with very low risk prostate cancer and a life expectancy estimated to be less than 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/1\">",
"     1",
"    </a>",
"    ]. Immediate definitive treatment with radiation therapy or radical prostatectomy is an alternative for patients desiring a more aggressive approach. Active surveillance may also be an option for patients with low-risk disease and a life expectancy of less than ten years.",
"   </p>",
"   <p>",
"    Although active surveillance is safer in the short run, it does induce significant concerns and anxiety. Many men who initially choose active surveillance decide on definitive treatment within one to two years despite the absence of progression.",
"   </p>",
"   <p>",
"    The key issues for patients who may be candidates for active surveillance include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate patient selection",
"     </li>",
"     <li>",
"      Frequency and type of monitoring required during surveillance and the ability and desire to comply with a surveillance schedule",
"     </li>",
"     <li>",
"      Criteria for initiating definitive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=see_link\">",
"     \"Active surveillance for men with early prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833704\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of RT for men with localized prostate cancer is to deliver a therapeutic dose of radiation to the tumor while minimizing radiation to normal tissues. Both external beam RT and brachytherapy are widely used as a single modality for clinically localized low risk prostate cancer. When used as the primary treatment modality, results with RT are similar to those with radical prostatectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link\">",
"     \"External beam radiation therapy for localized prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link\">",
"     \"Brachytherapy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definition of biochemical failure after RT is complex since some normal prostatic glandular tissue remains and serum PSA levels are unlikely to fall to undetectable levels following a course of RT. The Phoenix criteria define biochemical failure after either external beam RT or brachytherapy as a PSA rise of 2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or more above the nadir PSA after treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H6#H6\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832001\">",
"    <span class=\"h3\">",
"     External beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam RT utilizes an external source of radiation to treat the prostate gland and a margin of adjacent normal tissue. External beam RT is generally used alone for low risk clinically localized prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link\">",
"     \"External beam radiation therapy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833720\">",
"    <span class=\"h4\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional conformal RT (3D-CRT) techniques are considered standard and have replaced older two dimensional approaches for the definitive treatment of localized prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H2#H2\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'External beam RT techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple technical refinements of 3D-CRT may facilitate the administration of higher doses of radiation to the tumor and decrease toxicity to normal tissues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensity-modulated RT (IMRT) is an advanced form of 3D-CRT that has replaced older 3D-CRT techniques in many areas [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/3\">",
"       3",
"      </a>",
"      ]. IMRT utilizes a beam with varying intensity, in contrast to older forms of 3D-CRT techniques in which the dose rate is constant. Thus, IMRT can target a complex and irregular tumor volume more effectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"       \"Intensity-modulated radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Image-guided RT &ndash; Image-guided RT (IGRT) uses two- or three-dimensional imaging prior to each treatment to precisely locate the tumor and surrounding organs. IGRT thus further minimizes the margin of normal tissue that would otherwise need to be irradiated to allow for changing anatomic relationships.",
"     </li>",
"     <li>",
"      Proton-beam RT &ndash; Proton-beam RT uses charged particles (protons) to deliver high doses of RT to the target volume while limiting the \"scatter\" dose received by surrounding tissues. Although proton beam therapy is being more widely used in men with prostate cancer as new treatment facilities become available, there is currently no evidence that this approach offers any advantages over IMRT or IGRT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H9#H9\">",
"       \"External beam radiation therapy for localized prostate cancer\", section on 'Particle irradiation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833727\">",
"    <span class=\"h4\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity of external beam RT is low with contemporary 3D-CRT techniques. The main complications are briefly reviewed here and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H19#H19\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastrointestinal &ndash; Acute radiation proctitis of moderate or greater severity is reported in approximately 20 percent of men, depending upon its definition, the radiation dose, and treatment volume [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/4\">",
"       4",
"      </a>",
"      ]. This estimate is supported by an analysis from the Surveillance, Epidemiology, and End Results (SEER) database that found that approximately 17 percent of patients required a procedure such as colonoscopy following EBRT for prostate cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/3\">",
"       3",
"      </a>",
"      ]. If the pelvic lymph nodes are included in the treatment volume, radiation enteritis may also be observed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H20#H20\">",
"       \"External beam radiation therapy for localized prostate cancer\", section on 'Gastrointestinal'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Symptoms can include abdominal cramping, tenesmus, urgency, and frequent defecation. They can usually be controlled with antidiarrheal agents or topical antiinflammatory preparations. After RT is completed, acute symptoms usually subside within three to eight weeks.",
"      <br/>",
"      <br/>",
"      Long-term intestinal side effects persist in a low percentage of patients, manifested by persistent diarrhea, tenesmus, rectal urgency, or hematochezia. Rectal or anal strictures, ulcers, and perforation are rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"       \"Gastrointestinal toxicity of radiation therapy\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      Urinary &ndash; Approximately one-half of patients experience urinary frequency, dysuria, or urgency due to cystitis, urethritis, or both during external beam RT. Symptoms typically resolve within several weeks after the completion of therapy. Late side effects are uncommon. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H21#H21\">",
"       \"External beam radiation therapy for localized prostate cancer\", section on 'Urinary symptoms'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=see_link&amp;anchor=H9#H9\">",
"       \"Cystitis in patients with cancer\", section on 'Radiation cystitis'",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      Erectile dysfunction &ndash; The frequency of erectile dysfunction increases over time; by two years after external beam RT, 60 to 70 percent of men report moderate or more severe difficulties with sexual functioning [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/4\">",
"       4",
"      </a>",
"      ]. Other factors that can contribute to erectile dysfunction in this population include older age, intercurrent diseases (hypertension, cardiovascular disease, diabetes), and the use of neoadjuvant ADT (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H23#H23\">",
"       \"External beam radiation therapy for localized prostate cancer\", section on 'Sexual dysfunction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832036\">",
"    <span class=\"h3\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy directly implants a radioactive source within the prostate to treat the cancer, thus providing the highest dose of radiation over a very limited distance. Brachytherapy maximizes irradiation of the tumor while minimizing radiation to normal structures. Brachytherapy requires only a one or a limited number of treatments, rather than the daily therapy required by external beam RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link\">",
"     \"Brachytherapy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The radiation source is inserted into the prostate using a transperineal approach under transrectal ultrasound guidance. Low dose rate brachytherapy is delivered with permanently implanted radioactive seeds, typically using either iodine-125 or palladium-103.",
"   </p>",
"   <p>",
"    Alternatively, high dose rate brachytherapy uses a temporary radiation source such as iridium-192, which is inserted into the prostate through hollow catheters or needles that have been appropriately positioned and later removed. This form of brachytherapy typically requires a 48 hour hospitalization, while low dose rate brachytherapy can be completed in a single 90 minute outpatient procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832043\">",
"    <span class=\"h4\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriateness of brachytherapy for individual patients is based upon technical feasibility, the absence of coexistent urinary conditions, and the ability to adequately irradiate all disease. Brachytherapy alone is an appropriate option for men with low or intermediate-risk disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 1B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link&amp;anchor=H6#H6\">",
"     \"Brachytherapy for localized prostate cancer\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large prostate gland (&gt;60 g) is associated with a higher rate of treatment-related complications, including acute urinary retention, and is a relative contraindication to brachytherapy (",
"    <a class=\"graphic graphic_table graphicRef50303 \" href=\"UTD.htm?2/9/2204\">",
"     table 2",
"    </a>",
"    ). A course of ADT prior to brachytherapy is sometimes used prior to brachytherapy to reduce the volume of the prostate gland, although there is no evidence to demonstrate that this approach adds value and has the down side of exposing patients to the acute side effects of ADT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link&amp;anchor=H6#H6\">",
"     \"Brachytherapy for localized prostate cancer\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832057\">",
"    <span class=\"h4\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main complications following brachytherapy are genitourinary and gastrointestinal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link&amp;anchor=H20#H20\">",
"     \"Brachytherapy for localized prostate cancer\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary symptoms &ndash; Transient urinary frequency, urgency, and dysuria occur in the majority of patients, generally developing several days after implantation. Acute prostatic swelling causing urinary retention and requiring catheterization is uncommon. Late complications can include incontinence, urethral strictures, and urinary retention.",
"     </li>",
"     <li>",
"      Erectile dysfunction &ndash; The reported incidence of erectile dysfunction varies widely among men who were potent prior to brachytherapy (",
"      <a class=\"graphic graphic_table graphicRef82368 \" href=\"UTD.htm?33/40/34445\">",
"       table 3",
"      </a>",
"      ). The patient-reported frequency of erectile dysfunction is approximately 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link&amp;anchor=H26#H26\">",
"       \"Brachytherapy for localized prostate cancer\", section on 'Sexual dysfunction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      GI symptoms &ndash; Gastrointestinal toxicity is less common than genitourinary toxicity following brachytherapy. Late gastrointestinal complications of brachytherapy are seen in less than 10 percent of patients and include rectal urgency, bleeding or ulceration, bowel frequency, and prostatorectal fistulas [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H833938\">",
"    <span class=\"h2\">",
"     Radical prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical prostatectomy is an established option to treat localized prostate cancer, based upon high rates of long-term cancer control, acceptable perioperative morbidity and mortality, and side effects profile.",
"   </p>",
"   <p>",
"    The most widely used surgical techniques are the open retropubic radical prostatectomy and a minimally invasive radical prostatectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link\">",
"     \"Radical prostatectomy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All prostate tissue is removed during a successful radical prostatectomy. Postoperatively, detectable serum PSA using standard immunoassays is indicative of residual prostatic tissue, which presumably represents residual tumor tissue. The most widely accepted criterion for defining biochemical failure after radical prostatectomy is that of the American Urological Association (AUA), which defines a biochemical recurrence as a serum PSA &ge;0.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    that is confirmed by a second determination with a PSA &ge;0.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/7\">",
"     7",
"    </a>",
"    ]. Biochemical recurrence has a variable natural history, and not all men with a detectible PSA after RP require therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H5#H5\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radical prostatectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical staging based upon the digital rectal examination and potentially supplemented by imaging may fail to detect extracapsular extension, seminal vesical involvement, or lymph node involvement. Thus patients are restaged pathologically after radical prostatectomy. The management of patients with more extensively disease or positive margins based upon pathologic staging is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link\">",
"     \"Pathologic stage T3 and margin positive prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832064\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of most concern to men who undergo prostatectomy are urinary incontinence and impotence, which are due to damage to the urinary sphincter and penile nerves. The frequency of incontinence and erectile dysfunction depend in part upon the experience and expertise of the surgeon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H24077788#H24077788\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Complications and quality of life'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832071\">",
"    <span class=\"h4\">",
"     Urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of urinary incontinence following radical prostatectomy depends upon the definition of incontinence, the time elapsed since surgery, whether or not a nerve-sparing approach was used, and the source of the data (patient or physician reported). Based upon patient queries, some symptoms may be present in up to 25 percent or more of patients at one year and later, and 5 to 10 percent consider this to be a moderate or more severe problem [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H24077840#H24077840\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Urinary incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary incontinence is most common immediately after surgery, and there is a gradual return of function thereafter. Conservative measures (eg, pelvic floor muscle training and biofeedback) are often used in the months following radical prostatectomy in an effort to control symptoms while sphincter function is returning. For men with significant persistent incontinence, options include a urethral sling procedure or artificial urinary sphincter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832078\">",
"    <span class=\"h4\">",
"     Erectile dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of erectile dysfunction following retropubic radical prostatectomy depends upon the patient's age, preoperative level of sexual functioning, and whether or not nerve-sparing surgery was performed (",
"    <a class=\"graphic graphic_table graphicRef77589 \" href=\"UTD.htm?10/37/10845\">",
"     table 4",
"    </a>",
"    ). Erectile dysfunction is nearly universal if the erectile nerves are not preserved at surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H24077796#H24077796\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Impotence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The return of potency following a nerve-sparing procedure is gradual, and men may benefit from regular use of a phosphodiesterase-5 (PDE5) inhibitor. Although potency rates as high as 80 percent have been reported from individual centers performing nerve-sparing surgery on carefully selected men, the potency rates in broader populations are substantially lower. Furthermore, patient estimates of the frequency of erectile dysfunction are generally higher than physician-reported data.",
"   </p>",
"   <p>",
"    Erectile dysfunction can be treated with PDE-5 inhibitors, penile injection therapy, vacuum erection devices (VED), and implantation of a penile prosthesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=see_link\">",
"     \"Surgical treatment of erectile dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H834254\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832085\">",
"    <span class=\"h3\">",
"     Ablation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy and high-intensity focused ultrasound (HIFU) have been used to selectively destroy tissue, either by freezing or by generating local thermal energy. These ablation techniques can be applied either to the entire prostate gland or to focally destroy the part of the prostate gland thought to be involved by tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43000?source=see_link\">",
"     \"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of ablation with cryotherapy or HIFU as an alternative to radical prostatectomy or RT remains uncertain. Potential advantages in men with localized disease include the ability to destroy cancer cells using a relatively noninvasive procedure. As such, these procedures are associated with minimal blood loss and pain. There is also a more rapid posttreatment convalescence.",
"   </p>",
"   <p>",
"    Whether the long-term outcomes are equivalent to those with definitive surgery or RT is uncertain however. Additional experience and longer follow-up are required to compare the rate of disease control and side effects profiles with other treatment modalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H834295\">",
"    <span class=\"h3\">",
"     Androgen deprivation therapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the NCCN and the AUA both recommend that primary androgen deprivation therapy (ADT) not be included among standard options for the primary initial treatment of men with localized prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Androgen deprivation therapy (ADT) alone has been advocated for patients seeking active therapy but wishing to avoid the side effects of radical prostatectomy or RT. Studies advocating ADT alone for localized prostate cancer are retrospective, include limited patient numbers, have a short follow-up duration, and lack critical assessment of the side effects associated with ADT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increase in prostate cancer-specific mortality has been reported in two large series using primary ADT to treat localized prostate cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 19,271 men with prostate cancer in the Surveillance, Epidemiology and End Results (SEER) database compared outcomes in those managed with primary ADT with those managed conservatively without hormonal therapy (41 and 59 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients who were treated with surgery or RT in the six months after diagnosis were excluded. Men managed with primary ADT had an increased risk of prostate cancer-specific mortality compared to observation (HR 1.17, 95% CI 1.03-1.33), and there was no difference in overall mortality (HR 1.00, 95% CI 0.96-1.05). Subset analyses suggested that the only group that may have benefited was men with high grade tumors.",
"     </li>",
"     <li>",
"      A similar conclusion was drawn from a cohort from the National Center for Prostate Disease Research database, which included 2313 men with biopsy-confirmed, clinically localized (T1-T2) prostate cancer, of whom 569 chose ADT and 1744 chose expectant management [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/10\">",
"       10",
"      </a>",
"      ]. In a preliminary report, treatment with ADT was a significant predictor of all-cause death after controlling for follow-up time, year of diagnosis, age, race, PSA level, tumor characteristics, comorbidity, and secondary treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2951536\">",
"    <span class=\"h3\">",
"     Antiandrogen monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary antiandrogen monotherapy is not recommended for localized prostate cancer. Antiandrogen monotherapy was most extensively evaluated in the Early Prostate Cancer program in which 8113 men with localized (T1, T2) or locally advanced (T3, T4) nonmetastatic prostate cancer were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    or placebo in addition to standard care (watchful waiting, RP, or RT) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/11\">",
"     11",
"    </a>",
"    ]. At a median follow-up of 10 years, the improvement in progression-free survival in men with localized (T1, T2) disease was not statistically significant regardless of the initial management approach. In addition, there was no statistically significant difference in overall survival. In men with locally advanced (T3, T4) disease, PFS was improved but there was no statistically significant difference in overall survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11496867\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized clinical trials that provide adequate data comparing active surveillance, radiation therapy, brachytherapy, and radical prostatectomy for men with clinically localized, low-risk prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus comparisons between different treatment modalities rely upon interpretation of large, observational databases.",
"   </p>",
"   <p>",
"    Proper interpretation of observational series requires that studies have adequate follow-up, stratify patients based upon pretreatment criteria, utilize standard definitions for treatment success or failure, and contain adequate numbers of patients. The Prostate Cancer Results Study Group reviewed all studies published between 2000 and 2010 for published reports meeting those criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/12\">",
"     12",
"    </a>",
"    ]. That analysis suggested that brachytherapy was associated with better biochemical progression-free survival at five years, although it is unclear whether this may simply reflect differences in patient selection.",
"   </p>",
"   <p>",
"    Radical prostatectomy, external beam RT, and brachytherapy all provide biochemical relapse free survival of 80 percent or more in studies with follow-up of 5 to 10 years. Furthermore, more than 95 percent of patients remain free of local recurrence and distant metastases. Representative large observational studies illustrate the results in men with limited risk prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191026\">",
"    <span class=\"h2\">",
"     Radical prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results using radical retropubic prostatectomy to treat prostate cancer are illustrated by a retrospective series of 3283 men with low risk prostate cancer who were treated at the Mayo Clinic between 1987 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/13\">",
"     13",
"    </a>",
"    ]. Approximately two-thirds of these cases had clinical stage T1c disease and the remainder had T2a primary tumors; the mean pretreatment PSA was 5.4",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Median follow-up was 7.7 years.",
"   </p>",
"   <p>",
"    At five years, 90 percent of men were free from biochemical relapse, and at 10 years 82 percent remained progression free. Even among those who experienced a biochemical relapse, the prognosis for these low-risk patients was highly favorable. The overall rates of freedom from local recurrence were 98 and 97 percent at 5 and 10 years, respectively, and the freedom from systemic progression was 99.6 and 99 percent at 5 and 10 years, respectively.",
"   </p>",
"   <p>",
"    Additional data on the efficacy of radical prostatectomy come from a multi-institutional series of over 23,000 men who underwent radical prostatectomy for prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/14\">",
"     14",
"    </a>",
"    ]. In an analysis based upon surgical staging, the prostate cancer specific mortality for those with Gleason 6 or less lesions was approximately 1 percent at 15 years; similarly for those with pathologic T2N0 lesions, prostate cancer specific mortality was 0.8 to 1.5 percent at 15 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191033\">",
"    <span class=\"h2\">",
"     External beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes with external beam RT as a single modality are illustrated by a single institution series of 2047 men treated between 1998 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/15\">",
"     15",
"    </a>",
"    ]. The series included 446 patients with low-risk disease. RT was administered either by 3D-CRT or IMRT, with doses ranging from 66 to 86 Gy.",
"   </p>",
"   <p>",
"    The seven-year PSA relapse-free survival rate for low-risk disease patients was 90 percent. Both the distant metastasis-free and the cause-specific survival rates at seven years for the men with low risk disease were 99 percent. There was no statistically significant difference in outcome as a function of radiation dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191040\">",
"    <span class=\"h2\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results with low dose rate brachytherapy using permanent seed implantation are illustrated by a multi institution series of 2693 treated between 1988 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/16\">",
"     16",
"    </a>",
"    ]. Median follow-up was five years. Within this series, 1444 had low-risk disease. Two-thirds of patients were treated with iodine-125 and the remainder with palladium-103.",
"   </p>",
"   <p>",
"    The eight-year PSA relapse-free survival rate was 82 percent according to the ASTRO definition (three successive increases in the PSA after nadir reached) and 74 percent according to the Phoenix (nadir +2",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    definition. The eight-year distant metastasis free survival for the low-risk patients was 98 percent. Multivariate analysis confirmed the importance of an adequate dose of radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H834319\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with low-risk clinically localized prostate cancer, brachytherapy, external beam RT, and radical prostatectomy all provide an extremely high degree of freedom from local or distant recurrence with prolonged follow-up.",
"   </p>",
"   <p>",
"    The choice of therapy depends upon an informed patient decision incorporating knowledge about the potential advantages and disadvantages associated with each treatment approach along with personal preferences. Important advantages, disadvantages, and contraindications associated with each approach are summarized in the appended tables (",
"    <a class=\"graphic graphic_table graphicRef52491 \" href=\"UTD.htm?17/61/18396\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51287 \" href=\"UTD.htm?17/59/18364\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53124 \" href=\"UTD.htm?10/30/10732\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are no randomized trials that compare the effects of different treatment modalities on quality of life. Comparisons of outcomes from nonrandomized series are subject to multiple biases, imbalances in relevant prognostic factors, lack of central pathology review, and the progressive changes that may be present in this relatively older population. As a result, definitive comparisons are not possible.",
"   </p>",
"   <p>",
"    Early differences in effects on quality of life are illustrated by a multi-institutional, observational study of 1201 men treated for clinical",
"    <span class=\"nowrap\">",
"     T1/T2",
"    </span>",
"    prostate cancer from 2003 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/4\">",
"     4",
"    </a>",
"    ]. Active treatment for these men included radical prostatectomy (n = 601), external beam RT (n = 292), or brachytherapy (n = 306). Key observations from this study included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary symptoms &ndash; Symptoms of urinary irritation or obstruction (dysuria, weak stream, frequency) were seen after RT and were more common after brachytherapy than external beam RT. The incidence of these symptoms peaked at two months and was less common by two years after treatment. In contrast, incontinence was frequent after radical prostatectomy, with approximately two-thirds of patients requiring at least some pad use after two months. By two years, symptoms had resolved in most patients, although 20 percent still required some use of pads. Incontinence was much less common in patients treated with external beam RT or brachytherapy.",
"     </li>",
"     <li>",
"      Bowel function &ndash; Bowel symptoms, primarily urgency and frequency, were reported by 10 to 20 percent of patients treated with either external beam RT or brachytherapy. Although the incidence was highest at two months after treatment, symptoms persisted at two years in 7 to 16 percent of cases. Bowel symptoms were rare after radical prostatectomy.",
"     </li>",
"     <li>",
"      Sexual function &ndash; In patients managed with radical prostatectomy, some sexual dysfunction was present in approximately 90 percent of patients after two months and was a moderate or major problem in 60 percent. Some problems persisted in 60 percent after two years and was a moderate or big problem in 43 percent. For patients treated with RT (either external beam RT or brachytherapy), approximately 60 percent had some sexual dysfunction at two months, which persisted at two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar differences were seen in an observational study of 1655 men treated with either radical prostatectomy or RT between 1994 and 1995, in which functional status was assessed at baseline, 2, 5, and 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16969/abstract/17\">",
"     17",
"    </a>",
"    ]. Urinary symptoms and erectile dysfunction were significantly more frequent following radical prostatectomy, while bowel symptoms were more frequent following RT. However, there was a progressive decline in function in all three domains over time for both groups, and the differences were not statistically significant at 15 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H835294\">",
"    <span class=\"h1\">",
"     POST-TREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up surveillance after initial definitive treatment is an important component of patient management. Although most patients with low-risk clinically localized prostate cancer will remain disease-free, a minority will relapse with local",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distant disease.",
"   </p>",
"   <p>",
"    With the availability of sensitive testing for serum PSA, this may result in detection of recurrence at a time when successful salvage therapy is feasible.",
"   </p>",
"   <p>",
"    Follow-up after definitive treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/3/2099?source=see_link\">",
"       \"Patient information: Prostate cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=see_link\">",
"       \"Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=see_link\">",
"       \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anatomic extent of disease , serum PSA, and biopsy Gleason score are used for risk stratification which then guides the initial choice of therapy in conjunction with patient age, comorbidity, and personal preferences (",
"      <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"       table 1A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"       table 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with clinically localized, very low risk prostate cancer and a life expectancy of less than 20 years, we suggest active surveillance rather than immediate definitive therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, this approach is associated with a need for close follow-up and can create significant anxiety, causing many patients to subsequently choose definitive intervention even in the absence of progressive disease. Radiation therapy and radical prostatectomy are acceptable alternatives for patients preferring immediate definitive therapy. (See",
"      <a class=\"local\" href=\"#H833697\">",
"       'Active surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with low-risk prostate cancer and a life expectancy of greater than 10 years, definitive therapy (radical prostatectomy, brachytherapy, or external beam radiation therapy), or active surveillance may all be appropriate options. The choice of a specific approach requires a consideration of the benefits and risks associated with each approach, taking into account the patient's individual preferences and comorbidities. (See",
"      <a class=\"local\" href=\"#H833704\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H833938\">",
"       'Radical prostatectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H833697\">",
"       'Active surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a more limited life expectancy (less than 10 years) we suggest active surveillance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H833697\">",
"       'Active surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the efficacy with radical prostatectomy and radiation therapy are similar, there are important differences in the patterns of toxicity associated with these treatments. The advantages, disadvantages, and contraindications with each treatment modality are summarized in the attached tables (",
"      <a class=\"graphic graphic_table graphicRef52491 \" href=\"UTD.htm?17/61/18396\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef51287 \" href=\"UTD.htm?17/59/18364\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53124 \" href=\"UTD.htm?10/30/10732\">",
"       table 7",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H834319\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Irritative and obstructive urinary symptoms are more common after RT, particularly brachytherapy. Incontinence is more frequent after radical prostatectomy, but generally improves gradually after surgery.",
"     </li>",
"     <li>",
"      Bowel symptoms (urgency, frequency) are more common after external beam RT and brachytherapy than with radical prostatectomy.",
"     </li>",
"     <li>",
"      Erectile dysfunction is most frequent after radical prostatectomy. Bilateral nerve-sparing surgery diminishes but does not eliminate this risk. Erectile dysfunction is also common after both external beam RT and brachytherapy, and the incidence rises gradually following treatment. At 24 months, sexual symptom scores are similar among men treated with RP, RT, and brachytherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follow-up surveillance after initial definitive treatment is an important component of patient management since salvage may be feasible if recurrence is detected early. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link\">",
"       \"Follow-up surveillance during and after treatment for prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/2\">",
"      Dahabreh IJ, Chung M, Balk EM, et al. Active Surveillance in Men With Localized Prostate Cancer: A Systematic Review. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/3\">",
"      Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012; 307:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/4\">",
"      Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/5\">",
"      Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/6\">",
"      Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/7\">",
"      Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/8\">",
"      Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006; 106:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/9\">",
"      Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300:173.",
"     </a>",
"    </li>",
"    <li>",
"     Cullen J, Zhao,J, Chen Y, et al. Overall survival among prostate cancer patinets treated with primary androgen deprivation therapy versus expectant management (abstract). Data presented at the 3rd annual ASCO Prostate Cancer Symposium, Orlando, Florida, February 22-24, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/11\">",
"      et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programmer at a median follow-up of 9. 7 years. BJUI 2010; 105:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/12\">",
"      Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 Suppl 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/13\">",
"      Boorjian SA, Karnes RJ, Rangel LJ, et al. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/14\">",
"      Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/15\">",
"      Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/16\">",
"      Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007; 67:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16969/abstract/17\">",
"      Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368:436.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6940 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16969=[""].join("\n");
var outline_f16_36_16969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11496394\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H833689\">",
"      TREATMENT APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H833697\">",
"      Active surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H833704\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H832001\">",
"      - External beam RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H833720\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H833727\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H832036\">",
"      - Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832043\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832057\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H833938\">",
"      Radical prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H832064\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832071\">",
"      Urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832078\">",
"      Erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H834254\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H832085\">",
"      - Ablation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H834295\">",
"      - Androgen deprivation therapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2951536\">",
"      - Antiandrogen monotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11496867\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191026\">",
"      Radical prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191033\">",
"      External beam RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191040\">",
"      Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H834319\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H835294\">",
"      POST-TREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6940|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 1A\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 1B\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/9/2204\" title=\"table 2\">",
"      ABS guidelines prost brachyther",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/40/34445\" title=\"table 3\">",
"      PROSTQA probabilities of erection after brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/37/10845\" title=\"table 4\">",
"      PROSTQA probabilities of erection after radical prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/61/18396\" title=\"table 5\">",
"      Adv main Rx prost CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/59/18364\" title=\"table 6\">",
"      Disadv main Rx prost CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/30/10732\" title=\"table 7\">",
"      Contraind main Rx prost CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=related_link\">",
"      Active surveillance for men with early prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=related_link\">",
"      Brachytherapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43000?source=related_link\">",
"      Cryotherapy and other ablative techniques for the initial treatment of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=related_link\">",
"      Pathologic stage T3 and margin positive prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=related_link\">",
"      Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/3/2099?source=related_link\">",
"      Patient information: Prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/55/24441?source=related_link\">",
"      Prostate cancer in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=related_link\">",
"      Surgical treatment of erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_36_16970="Approach to acute vision loss in children";
var content_f16_36_16970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to acute vision loss in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16970/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16970/contributors\">",
"     Sabah Iqbal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16970/contributors\">",
"     Bruce L Klein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16970/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/36/16970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/36/16970/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/36/16970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute vision loss in children is frightening, not only for the patient and family, but also for the clinician. Blindness, especially if bilateral and permanent, represents a serious loss of function. Unfortunately, children may not present until they have significant loss of vision; very young children will not perceive declining vision until there is significant compromise and even school-age children compensate well. By the time vision loss is appreciated, the chance for recovery may be low.",
"   </p>",
"   <p>",
"    The approach to acute vision loss in children will be reviewed here. The approach to vision loss in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=see_link\">",
"     \"Approach to the adult with acute persistent visual loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;To achieve clear vision, light must follow an unhindered path from the front to the back of the eye, traveling through the cornea, aqueous humor, lens, and vitreous humor to the retina (",
"    <a class=\"graphic graphic_figure graphicRef67844 \" href=\"UTD.htm?16/57/17301\">",
"     figure 1",
"    </a>",
"    ). Refracted by the cornea and lens (and perhaps also by glasses or contact lenses), light is focused onto the retina where it is transformed into an electrochemical signal by photoreceptors and supporting cells. The signal is transmitted via the optic nerve through the visual pathways to the occipital lobes.",
"   </p>",
"   <p>",
"    Alterations in function of any of the structures along the visual pathway may cause vision loss. Pathology can be broadly divided into three major anatomic categories (",
"    <a class=\"graphic graphic_table graphicRef61855 \" href=\"UTD.htm?28/22/29036\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual media problems &ndash; Disorders of the cornea, anterior chamber, lens, and vitreous (",
"      <a class=\"graphic graphic_figure graphicRef67844 \" href=\"UTD.htm?16/57/17301\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Retinal problems &ndash; Vascular occlusion, retinal detachment, and retinal tumors",
"     </li>",
"     <li>",
"      Neuro-visual pathway problems &ndash; Optic nerve, chiasmal, and retrochiasmal pathology (",
"      <a class=\"graphic graphic_figure graphicRef74068 \" href=\"UTD.htm?24/19/24887\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Visual media",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Open globe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture or laceration of the globe from direct trauma is a common cause of acute vision loss that requires immediate ophthalmologic consultation. Paintball guns, BB guns, projectile toys, scissors, and recreational sharp objects are major culprits. Most victims are male. In many children, the injury is apparent on inspection (",
"    <a class=\"graphic graphic_picture graphicRef82383 \" href=\"UTD.htm?8/10/8354\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80118 \" href=\"UTD.htm?13/27/13745\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link&amp;anchor=H6#H6\">",
"     \"Open globe injuries: Emergent evaluation and initial management\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the patient with an open globe injury is summarized in a rapid overview (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"UTD.htm?16/28/16845\">",
"     table 2",
"    </a>",
"    ). Aggressive examination of the eye is contraindicated when globe rupture is suspected, as forced opening can lead to extrusion of ocular contents. The best course of action before an ophthalmologist can evaluate the child is to protect the eye with a hard shield that avoids pressure on the intraocular contents and to elevate the head of the bed to 30 degrees. Any visible foreign body should be left in place (",
"    <a class=\"graphic graphic_picture graphicRef80118 \" href=\"UTD.htm?13/27/13745\">",
"     picture 2",
"    </a>",
"    ). Eye drops should be avoided. An antiemetic (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum dose: 12 mg) is often prescribed to prevent vomiting and the associated increase in intraocular pressure. Intravenous pain medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    and sedation (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose: 4 mg) are often needed for pain and to prevent crying. The patient should be kept NPO (nil per os) for possible surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link\">",
"     \"Open globe injuries: Emergent evaluation and initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chemical burn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eye contact with acids or alkalis (",
"    <a class=\"graphic graphic_table graphicRef56411 \" href=\"UTD.htm?27/59/28604\">",
"     table 3",
"    </a>",
"    ) requires emergent evaluation and treatment to prevent permanent vision loss. Burn severity depends on the agent involved, amount of exposure, and depth of penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alkaline substances usually cause more severe damage than acids because of the ability to saponify phospholipid membranes (",
"    <a class=\"graphic graphic_table graphicRef56411 \" href=\"UTD.htm?27/59/28604\">",
"     table 3",
"    </a>",
"    ). This action leads to rapid epithelial cell death and caustic penetration into the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ]. Concentrated ammonia may cause anterior ocular structure injury after less than one minute of exposure, and lye can result in deep eye injury within three to five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/1\">",
"     1",
"    </a>",
"    ]. Acid burns cause coagulation necrosis that may result in extensive corneal scarring and ulceration that also pose a significant threat to vision.",
"   </p>",
"   <p>",
"    Patients with chemical eye burns present with decreased vision, moderate to severe eye pain, blepharospasm (inability to open the eyelids), conjunctival redness, and photophobia. In severe cases of alkaline exposure, the eye may appear white due to ischemia of the conjunctiva and scleral vessels (",
"    <a class=\"graphic graphic_picture graphicRef67858 \" href=\"UTD.htm?34/12/35023\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Emergent and thorough irrigation with sterile normal saline or water is mandatory until the pH of the tears is 6.5 to 7.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. Topical (eg, 0.5 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/19/36146?source=see_link\">",
"     proparacaine",
"    </a>",
"    , one drop into the affected eye) and intravenous analgesia (eg, IV",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) along with passive restraint facilitate irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The eyelids should be retracted for maximal exposure of the conjunctiva and cornea. Prolonged irrigation is best administered using a polymethylmethacrylate scleral lens (eg, Morgan&trade; lens), if available (",
"    <a class=\"graphic graphic_figure graphicRef51399 \" href=\"UTD.htm?28/19/28989\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74905 \" href=\"UTD.htm?25/57/26513\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63134 \" href=\"UTD.htm?39/43/40638\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53892 \" href=\"UTD.htm?20/54/21346\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts recommend that irrigation be performed initially for 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/1\">",
"     1",
"    </a>",
"    ]. The pH is then checked at the fornix (region between the conjunctiva and the lower eyelid). If the pH is still abnormal, then irrigation resumes for another 30 minutes. If the pH is normal, it should be remeasured at five minutes and then again at 30 minutes to ensure no recurrence of a pH imbalance. Care should be taken when concomitant globe rupture is suspected; irrigation should be more gentle and less forceful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some ophthalmologists also recommend a topical collagenase inhibitor based on experimental animal models showing benefits in rabbits and mice (eg, CaEDTA, N-acetyl cysteine, thymosin beta 4, and metalloproteinase inhibitors) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These agents act to minimize secondary inflammation and further damage to the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/4\">",
"     4",
"    </a>",
"    ]. However, human data is very limited, and these agents are not widely available for ocular use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute vision loss occurs rarely in children with infectious conjunctivitis, except for newborns with gonococcal conjunctivitis. However, differentiating conjunctivitis from keratitis (corneal inflammation), especially in patients who wear contacts or are suspected of Herpes simplex virus infection, is a major concern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=see_link&amp;anchor=H6#H6\">",
"     \"Gonococcal infection in the newborn\", section on 'Ophthalmia neonatorum'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of the red eye\", section on 'Infectious keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chlamydia trachomatis is the most frequent infectious cause of vision loss in developing countries, but trachoma is a more chronic condition, characterized by primary infection in childhood and the development of blindness during adulthood caused by corneal scarring from entropion and trichiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=see_link\">",
"     \"Epidemiology, diagnosis, and management of trachoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious keratitis (inflammation of the cornea) is most commonly caused by bacteria (especially Staphylococcus aureus and Pseudomonas aeruginosa), Herpes simplex virus, and adenovirus (epidemic keratoconjunctivitis or EKC).",
"   </p>",
"   <p>",
"    Bacterial keratitis occurs almost exclusively in contact lens wearers and may progress to corneal ulceration with hypopyon within 24 hours (",
"    <a class=\"graphic graphic_picture graphicRef53237 \" href=\"UTD.htm?23/35/24112\">",
"     picture 7",
"    </a>",
"    ). The diagnostic finding in bacterial keratitis is a corneal opacity or infiltrate (typically a round white spot) in association with red eye, photophobia, and foreign body sensation. Treatment requires urgent ophthalmological referral and prompt initiation of topical bactericidal antibiotics (ideally after obtaining cultures). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of the red eye\", section on 'Bacterial keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary herpes simplex virus keratoconjunctivitis is characterized by a dendritic pattern on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    staining of the cornea (",
"    <a class=\"graphic graphic_picture graphicRef55593 \" href=\"UTD.htm?7/6/7279\">",
"     picture 8",
"    </a>",
"    ). Multiple recurrences can lead to disciform scarring and subsequent vision loss. Although typically a self-limited process, duration of symptoms is reduced by topical or oral antiviral agents. Patients should be referred to an ophthalmologist within a few days for confirmation of diagnosis, ongoing vision monitoring, and possible addition of adjunctive topical glucocorticoid steroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33992?source=see_link\">",
"     \"Herpes simplex keratitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of the red eye\", section on 'Viral keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidemic keratoconjunctivitis (EKC) or adenoviral keratitis is typically a self-limited process without sequelae. However, patients can be quite miserable during active disease because of photophobia and foreign body sensation (",
"    <a class=\"graphic graphic_picture graphicRef80243 \" href=\"UTD.htm?22/4/22592\">",
"     picture 9",
"    </a>",
"    ). Rapid testing for adenovirus infection may help differentiate EKC from other types of keratitis. Referral to an ophthalmologist within days is warranted for confirmation of the diagnosis, vision monitoring, and treatment for those patients with decline in vision caused by subepithelial corneal infiltrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hyphema",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview summarizes the important clinical features and initial management of a traumatic hyphema (",
"    <a class=\"graphic graphic_table graphicRef74146 \" href=\"UTD.htm?28/28/29133\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hyphema, a collection of blood in the anterior chamber of the eye, typically results from blunt trauma to the eye in children (eg, hit by tennis ball or baseball). In addition to a hyphema, small objects (eg, paper clips, nails) tend to cause corneal abrasions or globe perforation, and large, hard objects (eg, fist, baseballs) often result in orbital fractures (",
"    <a class=\"graphic graphic_picture graphicRef78964 graphicRef59855 \" href=\"UTD.htm?13/0/13318\">",
"     picture 10A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71507 \" href=\"UTD.htm?41/26/42415\">",
"     picture 11",
"    </a>",
"    ). Spontaneous hyphema occurs rarely in children.",
"   </p>",
"   <p>",
"    A large hyphema may be noticeable when looking at the patient. In most instances, simply shining a tangential light into the anterior chamber reveals the characteristic crescenteric accumulation of blood. Diagnosis of a small, or microhyphema, requires the use of a slit lamp. The size of the hyphema correlates with visual outcome (",
"    <a class=\"graphic graphic_figure graphicRef60334 \" href=\"UTD.htm?8/13/8405\">",
"     figure 4",
"    </a>",
"    ). Permanent vision loss is also associated with the development of rebleeding or acute glaucoma. Patients with sickle hemoglobinopathies or bleeding disorder are at highest risk for permanent sequelae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17750?source=see_link&amp;anchor=H7#H7\">",
"     \"Traumatic hyphema: Epidemiology, anatomy, and pathophysiology\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a grade I or greater hyphema, sickle cell disease or trait, bleeding dyscrasia, or concern for an open globe need emergent evaluation by an ophthalmologist. In otherwise healthy children with a microhyphema, discussion with an ophthalmologist is recommended to address appropriate management and to ensure timely follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link&amp;anchor=H17#H17\">",
"     \"Traumatic hyphema: Clinical features and management\", section on 'Definitive management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Iritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iritis is a form of anterior uveitis that causes pain, photophobia, and sometimes vision loss. Traumatic iritis is not uncommon in children with blunt periorbital injuries. Other causes, such as rheumatologic conditions, tend to present subacutely or chronically. Slit lamp and funduscopic examination is necessary to establish the presence of uveitis. Treatment of traumatic iritis consists of cycloplegia (pharmacologic pupillary dilation), topical steroid drops (only for patients under the care of an ophthalmologist), and management of associated injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma defines a group of eye diseases that is traditionally characterized by elevated intraocular pressure (IOP) and is most prevalent in adults. Glaucoma occurs rarely in childhood and may present with a painful red eye. Children may also demonstrate photophobia, a cloudy cornea, or if under three years of age at onset, buphthalmos (an enlarged eye). Older children usually complain of visual loss. Early diagnosis and referral are crucial to ensure optimal visual outcome.",
"   </p>",
"   <p>",
"    Pediatric glaucoma is classified into primary and secondary types to provide a framework for the evaluation and management of individual patients (",
"    <a class=\"graphic graphic_table graphicRef56982 \" href=\"UTD.htm?23/16/23821\">",
"     table 5",
"    </a>",
"    ). Primary glaucomas are those with isolated angle malformations (trabeculodysgenesis). Secondary glaucoma either is acquired or related to an underlying ocular abnormality; it can occur at any age and may be present at birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of glaucoma in infants and children\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lens abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the clarity, or positioning (ectopic lentis) of the crystalline lens may alter the focus of light onto the retina, resulting in visual disturbance. Ectopic lentis is seen in pediatric patients with familial or idiopathic ectopia lentis, homocystinuria, Marfan syndrome, and trauma (",
"    <a class=\"graphic graphic_picture graphicRef77130 \" href=\"UTD.htm?10/53/11103\">",
"     picture 12",
"    </a>",
"    ). Lens clouding (cataract) does not occur acutely, except in the setting of trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=see_link\">",
"     \"Ectopia lentis (dislocated lens) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vitreous hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is the major cause of bleeding into the vitreous humor in children. In particular, abusive head trauma often results in this injury which may appear as a dome shaped hemorrhage that obscures the retina (",
"    <a class=\"graphic graphic_picture graphicRef69754 \" href=\"UTD.htm?38/62/39919\">",
"     picture 13",
"    </a>",
"    ). Other rare causes include spontaneous retinal tear, spontaneous vitreous detachment, and retinal neovascularization (as in poorly controlled diabetes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On physical examination, the reduction in vision is directly proportional to the amount of blood in the vitreous. If the hemorrhage is dense enough, there may be a decreased red reflex (the reddish orange reflection of light off of the retina when examining the eye with an ophthalmoscope), or the retina may not be visible with ophthalmoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endophthalmitis (internal eye infection) may complicate open globe injuries, eye surgery, and keratitis and is typically caused by surface pathogens. Patients present with decreased vision, pain, and red eye. A hypopyon may be detected (",
"    <a class=\"graphic graphic_picture graphicRef51972 \" href=\"UTD.htm?37/28/38351\">",
"     picture 14",
"    </a>",
"    ). Treatment consists of empiric broad spectrum antibiotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, maximum dose: 1 gram and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"     ceftazidime",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, maximum dose: 2 grams),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antifungal agents (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     Fluconazole",
"    </a>",
"    orally,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    IV, or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/60/12234?source=see_link\">",
"     voriconazole",
"    </a>",
"    IV). Emergent ophthalmologic consultation for possible intravitreal treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitrectomy is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link&amp;anchor=H9#H9\">",
"     \"Bacterial endophthalmitis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\", section on 'Approach to treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=see_link&amp;anchor=H866068368#H866068368\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\", section on 'Approach to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Retina",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinal detachment or hemorrhage &ndash; In young, healthy infants and children without a history of serious trauma, for example, an acceleration-deceleration mechanism such as a MVA with rollover, retinal hemorrhage or detachment is highly suggestive of child abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/8\">",
"       8",
"      </a>",
"      ]. Retinal injury rarely occurs spontaneously (eg, as a late complication of retinopathy of prematurity) or in the setting of unintentional trauma. Verbal patients may describe sudden onset of new floaters or black dots in their vision, often accompanied by flashes of light (photopsias). In its early stages, a detachment may present as a persistent missing portion of the monocular visual field. Once the macula (central retina) has become involved, visual acuity will be severely compromised. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=see_link\">",
"       \"Retinal detachment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"       \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Retinal detachment is not painful, and does not cause a red eye. There may be a dulling of the red reflex, and ophthalmoscopic examination may reveal the retina to be elevated with folds (",
"      <a class=\"graphic graphic_picture graphicRef77996 \" href=\"UTD.htm?39/17/40222\">",
"       picture 15",
"      </a>",
"      ). If the detachment is extensive, there may be a relative afferent pupillary defect (",
"      <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Central retinal artery occlusion &ndash; Although rare in pediatrics, central retinal artery occlusion (CRAO) presents with sudden, painless, severe, central",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paracentral monocular vision loss. In children and adolescents, retinal arterial occlusion is associated with sickle cell disease, congenital heart disease with right to left shunting, hypercoagulable states, thrombotic disorders, intravenous drug abuse, migraine, ocular trauma, pregnancy, and vasculitis (eg, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), systemic lupus erythematosus).",
"      <br/>",
"      <br/>",
"      Within minutes to hours of the occlusion, the only abnormality noted on ophthalmoscopy may be vascular narrowing. An embolus is visible in about 20 percent of patients with CRAO. After several hours, the inner layer of the retina becomes ischemic, turning milky white, except in the fovea which appears as a cherry-red spot (",
"      <a class=\"graphic graphic_picture graphicRef51342 \" href=\"UTD.htm?22/41/23187\">",
"       picture 16",
"      </a>",
"      ) when compared with the unaffected eye (",
"      <a class=\"graphic graphic_picture graphicRef66013 \" href=\"UTD.htm?41/37/42591\">",
"       picture 17",
"      </a>",
"      ). An afferent pupillary defect is typically present (",
"      <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"       figure 5",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Emergent ophthalmologic intervention to restore retinal circulation must occur as soon as possible to recover central vision. Therapeutic modalities include ocular massage, anterior chamber paracentesis, local arterial thrombolytic therapy, hyperbaric oxygen therapy, and surgical revascularization techniques. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=see_link&amp;anchor=H18#H18\">",
"       \"Central and branch retinal artery occlusion\", section on 'Acute treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central retinal vein occlusion &ndash; In children, the very rare occurrence of occlusion or thrombosis of the central retinal vein is associated with hyperviscosity, coagulopathy, and migraine. The cause of central retinal vein occlusion (CRVO) is often unknown. Thrombosis of the central retinal vein results in venous stasis, leading to disc swelling, diffuse nerve fiber layer and preretinal hemorrhage, and cotton wool spots that create a dramatic appearance, often called \"the blood and thunder\" fundus (",
"      <a class=\"graphic graphic_picture graphicRef72976 \" href=\"UTD.htm?32/53/33616\">",
"       picture 18",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4311?source=see_link&amp;anchor=H7614441#H7614441\">",
"       \"Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis\", section on 'Fundus examination'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In contrast to CRAO, the onset is typically subacute although vision loss may still be severe. When venous stasis is severe, infarction may occur due to slowed retinal blood flow on the arterial side. In this setting, a relative afferent pupillary defect is often present (",
"      <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4311?source=see_link&amp;anchor=H7614388#H7614388\">",
"       \"Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis\", section on 'Visual acuity'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Little data exists concerning the treatment of CRVO in children. The treatment of central retinal vein occlusion in adults is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38743?source=see_link\">",
"       \"Retinal vein occlusion: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retinal tumors &ndash; Retinoblastoma, the most common intraocular malignancy of childhood, exists in sporadic and heritable forms. Children with retinoblastoma frequently (but not always) present with leukocoria, also known as the amaurotic cat's eye reflex (",
"      <a class=\"graphic graphic_picture graphicRef56724 \" href=\"UTD.htm?0/7/124\">",
"       picture 19",
"      </a>",
"      ). Prompt referral to ophthalmology and other pediatric specialists (eg, pediatric oncology) is necessary to optimize visual outcome and survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of retinoblastoma\", section on 'Clinical presentation and diagnosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      While vascular malformations, such as hemangiomas, are common in children, hemangioma of the retina is quite rare. It may present with an acute loss of monocular vision due to hemorrhage. Sometimes the blood must be completely resorbed before the tortuous vessels of the hemangioma can be fully identified [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neuro-visual pathway",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orbital infections &ndash; Orbital cellulitis is localized posterior to the orbital septum (postseptal cellulitis,) and involves infection of the fat and muscle contained within the bony orbit. Sinusitis is the most common risk factor for orbital cellulitis because of the proximity of the ethmoid sinus to the orbit and the thin layer of bone (lamina papyracea) that separates the two spaces. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"       \"Orbital cellulitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27751?source=see_link&amp;anchor=H83430261#H83430261\">",
"       \"Preseptal cellulitis\", section on 'Anatomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H459379838#H459379838\">",
"       \"Orbital cellulitis\", section on 'Anatomy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Clinical manifestations of orbital cellulitis include fever, proptosis, a \"down and out\" position of the globe, limitation of eye movements, double vision,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vision loss due to orbital apex involvement. The diagnosis of orbital cellulitis is made by a combination of physical examination, including visual acuity and ocular motility assessment, and radiologic assessment with computed tomography of the orbit. Orbital infection warrants timely consultation with an ophthalmologist and otorhinolaryngologist (ear, nose, and throat surgeon). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"       \"Orbital cellulitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Complications of orbital cellulitis may develop rapidly and include localized abscesses of the subperiosteal bone and orbit, abscess extension to the orbital apex with visual loss (orbital apex syndrome),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extension intracranially via the valveless venous system resulting in intracranial abscess, meningitis, or cavernous sinus thrombosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H459379620#H459379620\">",
"       \"Orbital cellulitis\", section on 'Extraorbital extension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H459379581#H459379581\">",
"       \"Orbital cellulitis\", section on 'Complications'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The orbital apex syndrome refers to compression of the optic nerve with vision loss by a mass lesion in the orbital apex, the anatomic region containing the superior orbital fissure and optic canal. There may be no external signs of orbital infection other than vision loss. Sphenoid sinusitis, in particular, may be complicated by the orbital apex syndrome, due to the anatomic proximity of the sphenoid sinus to the optic canal [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Sphenoid sinusitis is easily misdiagnosed, because it can present with headache alone and without upper respiratory symptoms. Rarely, sphenoid sinus mucocele can exert pressure on the optic nerve with resultant vision loss [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cavernous sinus thrombosis &ndash; Septic thrombosis of the cavernous sinuses can lead to vision loss due to vascular compression of the optic nerve or thrombosis of ophthalmic vessels (",
"      <a class=\"graphic graphic_figure graphicRef61214 \" href=\"UTD.htm?0/51/821\">",
"       figure 6",
"      </a>",
"      ). The septic emboli initiating the thrombosis most commonly originate in infections involving the sinuses, face, ears, or oral cavity [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Orbital neoplasms &ndash; Neuroblastoma may metastasize to the orbital tissues, sometimes resulting in proptosis or periorbital ecchymosis and, rarely, can present with blindness [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. Visual loss during treatment has also been described and may represent a complication of therapy or progression of disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/18\">",
"       18",
"      </a>",
"      ]. Rhabdomyosarcoma most often presents in the head and neck region, and loss of vision may be the first sign of such a tumor. Because rhabdomyosarcoma tends to be a slow-growing tumor, vision typically declines gradually [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Idiopathic intracranial hypertension (IIH) &ndash; IIH (previously called pseudotumor cerebri) is characterized by increased intracranial pressure with compression of the optic nerve occurring in the absence of a space-occupying lesion or central nervous system infection. Its etiology is usually idiopathic, but associations with obesity and medications (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"       desmopressin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/33/19991?source=see_link\">",
"       isotretinoin",
"      </a>",
"      , steroids,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"       tetracycline",
"      </a>",
"      , vitamin A) have been reported. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=see_link\">",
"       \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Common findings of IIH include headache, transient visual defects, and papilledema (",
"      <a class=\"graphic graphic_picture graphicRef72814 graphicRef64616 \" href=\"UTD.htm?5/16/5381\">",
"       picture 20A-B",
"      </a>",
"      ). Untreated IIH can result in permanent vision loss due to increased pressure on the optic nerve, typically affecting peripheral vision. However, complete visual loss can happen at any time during the course of the illness. Treatment is aimed at rapid reduction of pressure on the optic nerve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"       \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link\">",
"       \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Optic neuritis &ndash; Optic neuritis (retrobulbar neuritis, papillitis) is characterized by inflammation, demyelinization, or degeneration of the optic nerve in association with significant vision loss that is typically monocular. Other findings include eye pain and photopsias (brief flashes of light), especially with movement of the eye, and papillitis (",
"      <a class=\"graphic graphic_picture graphicRef66013 \" href=\"UTD.htm?41/37/42591\">",
"       picture 17",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef50320 \" href=\"UTD.htm?31/5/31824\">",
"       picture 21",
"      </a>",
"      ). Outcome varies, depending on the etiology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=see_link\">",
"       \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"       \"Optic neuropathies\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      When it occurs, optic neuritis in children frequently follows a viral or bacterial infection, but quite often, there is no known etiology. Lyme disease, as an example, has been implicated in causing optic neuritis and blindness. With Lyme disease, loss of vision may result from inflammation of the optic nerve itself or from elevated intracranial pressure secondary to meningitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"       \"Optic neuropathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link\">",
"       \"Lyme disease: Clinical manifestations in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Optic neuritis may be the presenting sign of multiple sclerosis in children. Magnetic resonance imaging typically shows additional white matter lesions in these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Optic pathway glioma and other tumors &ndash; Optic glioma is the most common tumor of the optic nerve in childhood and is associated with neurofibromatosis type 1 (NF-1). These tumors typically represent pilocytic astrocytomas and grow slowly. However, significant visual field deficits are a potential indication for chemotherapy. Rarely, more rapid growth or hemorrhage can occur, compromising vision significantly. Optic pathway gliomas also arise in the optic chiasm, hypothalamus, or anterior third ventricle. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=see_link\">",
"       \"Optic pathway glioma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Acute lymphoblastic leukemia (ALL) may infiltrate the optic nerve and eye in children [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Like the testicle, the eye is an important \"sanctuary\" site for leukemic cells where leukemia may recur after therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Rarely, non-Hodgkin's lymphoma has presented with acute vision loss due to direct optic nerve compression by tumor mass or optic atrophy due to increased intracranial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/19,22\">",
"       19,22",
"      </a>",
"      ]. Third, fourth, and sixth nerve palsies may also occur.",
"     </li>",
"     <li>",
"      Optic nerve avulsion &ndash; Optic nerve avulsion from penetrating or blunt trauma is a rare cause of blindness. Any sharp object penetrating the globe can cause optic nerve avulsion [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/23\">",
"       23",
"      </a>",
"      ]. Optic nerve avulsion may occur even in cases where the globe appears intact and likely results from a forced rotational movement or a rapid rise in intraocular pressure.",
"     </li>",
"     <li>",
"      Optic chiasm pathology &ndash; Involvement of the chiasm is suggested by visual loss of any type associated with pituitary dysfunction, or by a bitemporal hemianopia (",
"      <a class=\"graphic graphic_figure graphicRef74068 \" href=\"UTD.htm?24/19/24887\">",
"       figure 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Compressive chiasmal lesions typically cause gradual decline in vision, as they impinge upon the chiasm, optic nerve, or optic tract. Peripheral vision loss is often asymptomatic until visual acuity is compromised. Thus, most visual complaints are of gradual blurring or dimming of vision. Sudden chiasmal vision loss is less common, and implies a rapidly expanding mass, or an infectious, vascular, or inflammatory cause. Craniopharyngioma is the most common tumor involving the optic chiasm in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=see_link\">",
"       \"Craniopharyngioma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retro-chiasm pathology &ndash; Brain lesions in the region of the optic tract, the lateral geniculate body, the optic radiations, or the visual cortex produce a loss of vision on one side of both visual fields (",
"      <a class=\"graphic graphic_figure graphicRef74068 \" href=\"UTD.htm?24/19/24887\">",
"       figure 2",
"      </a>",
"      ). The visual field defect is relatively symmetric, and respects the vertical midline. No other eye abnormalities are seen. The most common causes are stroke or hemorrhage into a brain tumor.",
"      <br/>",
"      <br/>",
"      Meningitis or occipital cerebral abscess can also result in blindness, due to various mechanisms, especially cortical damage [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Extensive bilateral damage to the cerebral visual pathways (eg, following prolonged hypoxia or shock) may result in complete loss of vision (cortical blindness). Patients with cortical blindness due to carbon monoxide poisoning have a history of exposure with elevated carboxyhemoglobin or abnormal measured cooximetry values. Rarely, dialysis patients with profound uremia experience cortical blindness that resolves with dialysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8456?source=see_link&amp;anchor=H2#H2\">",
"       \"Eye disorders associated with chronic kidney disease\", section on 'Ophthalmoscopic evaluation and general findings in chronic kidney disease and end-stage renal disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Functional visual loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients describing visual loss without an organic basis are said to have \"functional\" visual loss. Patients who are purposely feigning blindness are malingerers, whereas those who truly perceive blindness have a conversion disorder. The visual loss may be monocular or binocular, total or sub-total. Malingerers have been known to pharmacologically alter pupillary function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H2#H2\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical child with functional visual loss is a female teenager [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/26\">",
"     26",
"    </a>",
"    ]. These patients walk more carefully through the waiting area or examination room and are not likely to bump into objects or hurt themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/27\">",
"     27",
"    </a>",
"    ]. While older patients with hysterical blindness are recognizable by \"la belle indifference,\" a seeming lack of concern with their sudden blindness, younger children may express great worry about their symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/28\">",
"     28",
"    </a>",
"    ]. The ocular examination is entirely normal. The ability to elicit nystagmus with an optokinetic drum is one method to prove the presence of vision to skeptical parents. Management generally includes referral for psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/26,28\">",
"     26,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversion disorders are well described in the pediatric population and are thought to be a result of involuntary somatization of unresolved psychological issues [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Conversion reactions frequently stem from conflicts surrounding school changes, new social settings, or family stress [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Psychiatric comorbidity (eg, depression, posttraumatic stress disorder) is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated methanol overdose results in specific ocular toxicity characterized by destruction of optic nerve and pigmented retinal epithelial cells. Visual disturbances seem to derive from production of the formate metabolite and may occur up to 72 hours after ingestion. Patients describe several visual disturbances including blind spots, snow field vision, and loss of color vision. An afferent pupillary defect (",
"    <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"     figure 5",
"    </a>",
"    ) is an ominous and late sign of advanced methanol poisoning. Eye examination in methanol poisoning may also reveal mydriasis, a retinal sheen due to retinal edema, and hyperemia of the optic disk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"     \"Methanol and ethylene glycol poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any ingestion that causes significant occipital cerebral ischemia or hypoxia may cause cortical blindness. Mechanisms include interference with cerebral oxygen delivery (eg, carbon monoxide), production of shock (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"     nifedipine",
"    </a>",
"    ), local cerebral vasospasm (eg, amphetamines), and direct neurotoxicity (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Transient vision loss",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Migraine &ndash; Migraine is the most common cause of transient bilateral vision loss (TBVL) in adolescents and young adults. Headache and positive visual phenomena, such as scintillations, usually occur in these patients. The classic migraine aura typically lasts 20 to 30 minutes, rarely as long as an hour, and has a characteristic build-up, or evolution, a feature lacking in other causes of TBVL (eg, seizure). The mechanism of visual loss in migraine is thought to be neuronal depression after a period of cortical excitation (\"spreading depression of Leao\") as well as transient cerebral vasospasm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H203275055#H203275055\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine aura'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649620#H130649620\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Pathophysiology'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In young children, migraines may be associated with confusion, vomiting, visual changes, and hemiplegia that may follow mild head trauma and typically resolve within 24 hours. A strong family or personal history of migraines is often present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H16#H16\">",
"       \"Classification of migraine in children\", section on 'Migraine variants'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Rarely, ocular migraine may cause monocular vision loss or the perception of bright light (photopsia) or scintillations in one eye only, followed within one hour by a migrainous headache. The neurologic symptoms are fully reversible. The headache is typically ipsilateral and periorbital. Visual symptoms may occur without headache. Vision usually recovers in this condition, although permanent visual loss may occur. Funduscopic examination in this condition is abnormal. The retina appears pale and retinal vessels may be constricted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H14#H14\">",
"       \"Classification of migraine in children\", section on 'Retinal migraine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Head trauma &ndash; Transient cortical defects, such as cortical blindness and acute confusional states, have been reported in association with minor head injury. These deficits are thought to be secondary to vascular hyperreactivity and may be trauma-induced (eg, occipital concussion) or migraine-equivalent phenomena. A typical case is a child with head trauma followed by loss of consciousness who awakens blind, but whose blindness resolves completely within hours of the event. If neurologic symptoms persist, a full evaluation for brain injury must ensue. Permanent vision loss can result from intracranial injury [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link&amp;anchor=H16#H16\">",
"       \"Minor head trauma in infants and children\", section on 'Other clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizure &ndash; Benign occipital epilepsy of childhood, sometimes referred to as Gastaut-type, has a mean age of presentation of eight to nine years (range 3 to 16 years). Seizures are typically brief (1 to 10 minutes) and often include visual symptoms, such as blindness or visual hallucinations. Hemiclonic activity, automatisms, migraine-like headache, and aversive movements may also occur, and seizures may secondarily generalize. An abnormal electroencephalogram (EEG) confirms the diagnosis. Antiepileptic drug treatment is more often prescribed than in other partial epilepsy syndromes since the duration of epilepsy is longer and seizures can be frequent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/57/921?source=see_link&amp;anchor=H14#H14\">",
"       \"Benign partial epilepsies of childhood\", section on 'Benign occipital epilepsy of childhood'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key historical information includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Timing &ndash; Ascertaining the exact moment when vision was lost can be helpful diagnostically, but difficult to pinpoint historically. Because children typically compensate well, especially when only one eye is affected, they may not realize that sight is deteriorating until seriously impaired [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/19,32\">",
"       19,32",
"      </a>",
"      ]. If the normal eye is inadvertently covered, a longstanding or gradual loss of vision in the other eye may be mistaken for acute loss. School records documenting prior visual acuity may be useful.",
"     </li>",
"     <li>",
"      Binocular versus monocular vision loss &ndash; True binocular vision loss in the absence of trauma suggests a retrochiasmal visual pathway disorder.",
"     </li>",
"     <li>",
"      Trauma &ndash; Mild trauma can cause corneal abrasion or uveitis; more severe trauma can cause hyphema, vitreous hemorrhage, traumatic cataract, retinal detachment, or traumatic optic neuropathy. Trauma with a sharp or blunt object may produce an open globe. Head trauma may cause a transient loss of vision due to occipital concussion. In infants and small children, abusive head injury is an all too frequent cause of retinal and vitreous hemorrhages with papilledema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"       \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain &ndash; The quality of the eye pain may assist in diagnosis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Keratitis &ndash; Sharp superficial eye pain",
"     </li>",
"     <li>",
"      Acute glaucoma &ndash; Deep brow ache with nausea and vomiting",
"     </li>",
"     <li>",
"      Endophthalmitis &ndash; Deep boring pain",
"     </li>",
"     <li>",
"      Optic neuritis or orbital infection &ndash; Pain worse with eye movement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache &ndash; Patients with migrainous vision loss or idiopathic intracranial hypertension typically have an associated headache.",
"     </li>",
"     <li>",
"      Photophobia &ndash; Patients with media disorders, including keratitis, traumatic hyphema, and iritis typically have intense photophobia.",
"     </li>",
"     <li>",
"      Fever &ndash; Fever in conjunction with proptosis and pain on eye motion suggests an orbital infection.",
"     </li>",
"     <li>",
"      Contact lens wear &ndash; Contact lens wear is a risk factor for microbial keratitis, especially with soft lenses and when lenses are used improperly (poor hygiene, overnight wear, contaminated solutions). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link&amp;anchor=H11#H11\">",
"       \"Evaluation of the red eye\", section on 'Bacterial keratitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Photopsias &ndash; Patients with optic neuritis often describe photopsias (flashes of light) with pain on eye movement. Painless photopsias occur in patients with retinal detachment. Recent treatment with eye drops: over-treatment of both conjunctivitis and keratitis with multiple topical medications can result in toxic ulcers, which can threaten sight [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Associated symptoms &ndash; Neurologic deficits can accompany a migraine headache, seizure, stroke (homonymous defect), or multiple sclerosis (optic neuritis). Nausea and vomiting accompany severely elevated intraocular pressure and intraocular trauma (eg, traumatic hyphema). Rhinorrhea is common when tearing is present. Some patients with monocular or binocular vision loss complain of a vague sense of disorientation or difficulty with balance and depth perception.",
"     </li>",
"     <li>",
"      Past medical history &ndash; Conditions that predispose to specific types of vision loss include sickle cell disease (stroke, central retinal artery occlusion, glaucoma in the setting of traumatic hyphema), thrombotic disorders (cavernous sinus thrombosis, central retinal vein thrombosis), migraine (transient vision loss), partial seizures (benign occipital epilepsy of childhood), and psychiatric illness (conversion disorder).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected globe rupture or laceration should not undergo lid retraction or other procedures that may apply pressure to the eye. In addition, topical drops (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    , anesthetic drops) should not be applied except by an ophthalmologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link&amp;anchor=H15#H15\">",
"     \"Open globe injuries: Emergent evaluation and initial management\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduced ambient light and parental presence facilitate cooperation in the child. Once an open globe is excluded, topical analgesia may be provided, as needed, for pain and photophobia.",
"   </p>",
"   <p>",
"    The clinician should perform a complete ocular examination, starting away from the patient and evaluating each of the anatomical components of vision in turn. Potentially frightening or painful procedures (eg, bright illumination of the injured eye, funduscopic examination, lid retraction) should be performed later in the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/34\">",
"     34",
"    </a>",
"    ]. Key aspects of the examination include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link&amp;anchor=H12#H12\">",
"     \"The pediatric physical examination: HEENT\", section on 'Eyes'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient level of consciousness and ability to cooperate with the examination",
"     </li>",
"     <li>",
"      Inspection of the orbit and surrounding structures",
"     </li>",
"     <li>",
"      Visual acuity of each eye independently",
"     </li>",
"     <li>",
"      Extraocular movement",
"     </li>",
"     <li>",
"      Confrontational visual fields",
"     </li>",
"     <li>",
"      Pupillary appearance and response to light (including the swinging flashlight test, (",
"      <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"       figure 5",
"      </a>",
"      ))",
"     </li>",
"     <li>",
"      Evaluation of anterior chamber depth and presence of visible hyphema using a penlight",
"     </li>",
"     <li>",
"      Direct funduscopic examination",
"     </li>",
"     <li>",
"      Eversion of the eyelids",
"     </li>",
"     <li>",
"      Slit lamp examination of the eye (in the older patient and by experienced clinicians)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children younger than two to three years of age, visual behavior (",
"    <a class=\"graphic graphic_table graphicRef73947 \" href=\"UTD.htm?6/12/6348\">",
"     table 6",
"    </a>",
"    ) rather than visual acuity is assessed. The goal is to determine whether visual behavior is normal for age and whether vision is equal between the two eyes. Visual behavior can be tested in all children. Even very young infants demonstrate visual fixation if an appropriate target (eg, the human face) is used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to monocular or binocular diminished visual acuity, key abnormal findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Periorbital swelling (eye trauma, orbital infection)",
"     </li>",
"     <li>",
"      Signs of an open globe (eg, eccentric or peaked pupil, obvious laceration, protruding intraocular foreign body, or evidence of extrusion of ocular contents). If present, a stiff, protective shield should be applied and an ophthalmologist should be consulted immediately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link&amp;anchor=H22#H22\">",
"       \"Open globe injuries: Emergent evaluation and initial management\", section on 'Initial emergency assessment and treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proptosis (orbital infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mass)",
"     </li>",
"     <li>",
"      Conjunctival injection (conjunctivitis, keratitis, corneal injury,",
"      <span class=\"nowrap\">",
"       uveitis/iritis,",
"      </span>",
"      endophthalmitis, or glaucoma)",
"     </li>",
"     <li>",
"      Blood (hyphema) or pus (hypopyon) in the anterior chamber",
"     </li>",
"     <li>",
"      Pain on extraocular movement (orbital infection, optic neuritis)",
"     </li>",
"     <li>",
"      Homonymous visual field abnormalities (retrochiasmal disorders)",
"     </li>",
"     <li>",
"      Afferent pupillary defect (unilateral optic nerve pathology) (",
"      <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"       figure 5",
"      </a>",
"      ) &ndash; To compare pupillary reflexes, the clinician should examine the pupils from such a distance that both eyes are visible at once [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal red reflex &ndash; A dull reflex indicates obstruction anterior to the retina, and can be caused by tumor or hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/36\">",
"       36",
"      </a>",
"      ]. A white reflex (leukocoria) is worrisome for cataract, Coats disease, intraocular tumor, or retinal detachment (",
"      <a class=\"graphic graphic_picture graphicRef56724 \" href=\"UTD.htm?0/7/124\">",
"       picture 19",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal funduscopic examination &ndash; Pallor (central retinal artery occlusion), abnormal vessels, retinal hemorrhage (abusive head trauma in young infants), papilledema (idiopathic intracranial hypertension, abusive head trauma, intracranial mass lesions), papillitis (optic neuritis).",
"     </li>",
"     <li>",
"      Evidence of conversion disorder &ndash; Patients with hysterical blindness carefully avoid falling or bumping into things. Optokinetic reflex is intact. Additionally, a mirror placed in front of the patient's eyes can be tilted in different directions and a seeing patient's eyes will move [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       Fluorescein",
"      </a>",
"      staining identifies corneal defects (eg, corneal abrasion or keratitis), but is contraindicated in the patient with an open globe.",
"     </li>",
"     <li>",
"      Slit lamp examination is best for identifying microhyphema, hypopyon, iritis, and lens abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=see_link\">",
"       \"Slit lamp examination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When a complete ocular examination in a truly blind patient is normal, cortical blindness is the presumptive diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tonometry (intraocular pressure measurement) may be performed by an appropriately trained emergency physician or by an ophthalmologist. Ophthalmology consultation is generally needed to obtain indirect funduscopy, formal visual field testing, or visual evoked responses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific laboratory tests (eg, CBC, blood culture, Lyme titers, toxicology screen, lumbar puncture) and diagnostic tests (eg, head CT, MRI, EEG) should be obtained based on clinical suspicion.",
"   </p>",
"   <p>",
"    High resolution, thin-slice, orbital computed tomography with coronal images is preferred for evaluation of orbital trauma, bony injuries, orbital cellulitis, and intraocular foreign bodies. Magnetic resonance imaging (MRI) is best for identifying optic nerve tumors, optic neuritis, and other soft tissue ocular anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/36/16970/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. MRI should not be performed in patients with metallic intraocular foreign bodies. Plain radiographs or orbital CT should be obtained before MRI to exclude this diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with acute vision loss must undergo a rapid evaluation to determine the most likely etiology (",
"    <a class=\"graphic graphic_algorithm graphicRef64435 graphicRef64873 \" href=\"UTD.htm?30/4/30788\">",
"     algorithm 1A-B",
"    </a>",
"    ). Life-threatening causes include intracranial injury, intracranial mass lesion with impingement of the neuro-visual pathway, malignant eye tumors, methanol poisoning, and carbon monoxide poisoning. Patients with intraocular trauma, chemical burns, orbital infection, central retinal artery occlusion, and endophthalmitis warrant emergent ophthalmologic consultation in order to provide the best chance for preservation of vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monocular vision loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic injury is a key cause of monocular vision loss in children (",
"    <a class=\"graphic graphic_algorithm graphicRef64435 \" href=\"UTD.htm?24/13/24784\">",
"     algorithm 1A",
"    </a>",
"    ). Initial assessment should identify signs of a ruptured or lacerated globe. If present, the patient should have an eye shield placed and emergent ophthalmologic consultation. Patients without concern for an open globe require a complete eye examination to evaluate for serious corneal injury (eg, chemical burn) or traumatic hyphema. Damage to posterior structures (eg, lens, retina, vitreous, optic nerve) often coexists with corneal chemical burns or traumatic hyphema. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Chemical burn'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Open globe'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Hyphema'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Careful eye examination helps differentiate the causes of atraumatic monocular vision loss:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with atraumatic painful vision loss and a red eye warrant measurement of intraocular pressure (IOP). Increased IOP identifies glaucoma and may occur with uveitis and endophthalmitis. Patients with normal IOP may have keratitis and IOP may also be normal in patients with uveitis, or endophthalmitis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glaucoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Conjunctivitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Keratitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Iritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain on extraocular movement without conjunctival redness may indicate orbital infection, cavernous sinus thrombosis, or optic neuritis.",
"     </li>",
"     <li>",
"      Leukocoria is seen in patients with an intraocular tumor or cataract. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Retina'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Lens abnormality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal funduscopic examination may provide clues to the diagnosis for vitreous hemorrhage, central retinal artery occlusion (pale optic disk and cherry red spot), central retinal vein occlusion (blood and thunder fundus), retinal hemorrhage or detachment, or idiopathic intracranial hypertension or central nervous system mass lesions (papilledema). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Retina'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Vitreous hemorrhage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Neuro-visual pathway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with monocular vision loss, a normal eye examination, and preserved optokinetic reflex have functional blindness (conversion disorder). Patients with ocular migraine demonstrate retinal pallor and transient monocular vision loss often with unilateral headache. Acute optic nerve impingement caused by a rapidly expanding CNS lesion rarely causes monocular vision loss without abnormality on eye examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Binocular vision loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma remains an important consideration in the evaluation of binocular vision loss (",
"    <a class=\"graphic graphic_algorithm graphicRef64873 \" href=\"UTD.htm?32/38/33391\">",
"     algorithm 1B",
"    </a>",
"    ). Bilateral eye trauma may cause total loss of vision. Etiologies are the same as for monocular vision loss (",
"    <a class=\"graphic graphic_algorithm graphicRef64435 \" href=\"UTD.htm?24/13/24784\">",
"     algorithm 1A",
"    </a>",
"    ). Patients who have vision loss in conjunction with head trauma warrant neuroimaging to differentiate among intracranial injury with increased intracranial pressure, occipital intracranial injury, and occipital concussion.",
"   </p>",
"   <p>",
"    Patients with conversion disorder have a normal eye examination and intact optokinetic nystagmus. Transient vision loss with a history of a recent seizure and interictal occipital abnormalities on EEG indicates benign occipital epilepsy of childhood. Transient vision loss characterized by visual scintillations with a progressive build up followed by headache is seen in patients with migraine.",
"   </p>",
"   <p>",
"    Papilledema on funduscopic examination indicates increased intracranial pressure (ICP) and is seen in patients with idiopathic intracranial hypertension or central nervous system mass lesion. Circumferential narrowing of peripheral vision suggests diffusely increased ICP without interruption of the neuro-visual pathway. Bilateral visual field deficits that respect the vertical midline (eg, homonymous hemianopia) identify tumors with disruption of the neuro-visual pathway at or behind the optic chiasm.",
"   </p>",
"   <p>",
"    Vision loss due to methanol ingestion occurs up to 72 hours after ingestion and is associated with a serum osmolal gap",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an anion gap acidosis.",
"   </p>",
"   <p>",
"    Any central nervous system process that results in bilateral occipital lobe hypoxia or ischemia can cause cortical blindness. Patients with cortical blindness due to carbon monoxide poisoning have a history of exposure with elevated carboxyhemoglobin or abnormal measured cooximetry values. Rarely, dialysis patients with profound uremia experience cortical blindness that resolves with dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8456?source=see_link&amp;anchor=H2#H2\">",
"     \"Eye disorders associated with chronic kidney disease\", section on 'Ophthalmoscopic evaluation and general findings in chronic kidney disease and end-stage renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute vision loss in children is frightening, not only for the patient and family, but also for the clinician. Blindness, especially if bilateral and permanent, represents a serious loss of function. Alterations in function of any of the structures along the visual pathway may cause vision loss. Pathology can be broadly divided into three major anatomic categories (",
"    <a class=\"graphic graphic_table graphicRef61855 \" href=\"UTD.htm?28/22/29036\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Media problems &ndash; Disorders of the cornea, anterior chamber, lens, vitreous, and uvea (",
"      <a class=\"graphic graphic_figure graphicRef67844 \" href=\"UTD.htm?16/57/17301\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Retinal problems &ndash; Vascular occlusion, retinal detachment, and retinal tumors.",
"     </li>",
"     <li>",
"      Neuro-visual pathway problems &ndash; Optic nerve, chiasmal, and retrochiasmal pathology (",
"      <a class=\"graphic graphic_figure graphicRef74068 \" href=\"UTD.htm?24/19/24887\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The approach to monocular and binocular vision loss is summarized in the algorithms (",
"      <a class=\"graphic graphic_algorithm graphicRef64435 \" href=\"UTD.htm?24/13/24784\">",
"       algorithm 1A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef64873 \" href=\"UTD.htm?32/38/33391\">",
"       algorithm 1B",
"      </a>",
"      ). Rapid determination of a trauma history, exclusion of an open globe, and early recognition and irrigation of ocular chemical burns to the eye are essential aspects of initial treatment. Patients with signs of intraocular trauma, chemical burns, orbital infection, central retinal artery occlusion, and endophthalmitis warrant emergent ophthalmologic consultation to provide the best chance for preservation of vision.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/1\">",
"      Spector J, Fernandez WG. Chemical, thermal, and biological ocular exposures. Emerg Med Clin North Am 2008; 26:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/2\">",
"      Duffy B. Managing chemical eye injuries. Emerg Nurse 2008; 16:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/3\">",
"      Knoop K, Trott A. Ophthalmologic procedures in the emergency department--Part I: Immediate sight-saving procedures. Acad Emerg Med 1994; 1:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/4\">",
"      Rozenbaum D, Baruchin AM, Dafna Z. Chemical burns of the eye with special reference to alkali burns. Burns 1991; 17:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/5\">",
"      Naradzay J, Barish RA. Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/6\">",
"      Sosne G, Christopherson PL, Barrett RP, Fridman R. Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci 2005; 46:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/7\">",
"      Berman MB. Collagenase inhibitors: rationale for their use in treating corneal ulceration. Int Ophthalmol Clin 1975; 15:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/8\">",
"      Levin AV. Retinal hemorrhage in abusive head trauma. Pediatrics 2010; 126:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/9\">",
"      Naftchi S, la Cour M. A case of central visual loss in a child due to macular cavernous haemangioma of the retina. Acta Ophthalmol Scand 2002; 80:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/10\">",
"      el-Sayed Y, al-Muhaimeid H. Acute visual loss in association with sinusitis. J Laryngol Otol 1993; 107:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/11\">",
"      Postma GN, Chole RA, Nemzek WR. Reversible blindness secondary to acute sphenoid sinusitis. Otolaryngol Head Neck Surg 1995; 112:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/12\">",
"      Casteels I, De Loof E, Brock P, et al. Sudden blindness in a child: presenting symptom of a sphenoid sinus mucocele. Br J Ophthalmol 1992; 76:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/13\">",
"      Cannon ML, Antonio BL, McCloskey JJ, et al. Cavernous sinus thrombosis complicating sinusitis. Pediatr Crit Care Med 2004; 5:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/14\">",
"      Quisling SV, Mawn LA, Larson TC 3rd. Blindness associated with enlarging mycotic aneurysm after cavernous sinus thrombosis. Ophthalmology 2003; 110:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/15\">",
"      Watkins LM, Pasternack MS, Banks M, et al. Bilateral cavernous sinus thromboses and intraorbital abscesses secondary to Streptococcus milleri. Ophthalmology 2003; 110:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/16\">",
"      Belgaumi AF, Kauffman WM, Jenkins JJ, et al. Blindness in children with neuroblastoma. Cancer 1997; 80:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/17\">",
"      McGirt MJ, Cowan JA Jr, Gala V, et al. Surgical reversal of prolonged blindness from a metastatic neuroblastoma. Childs Nerv Syst 2005; 21:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/18\">",
"      Varma D, George N, Livingston J, et al. Acute visual loss as an early manifestation of metastatic neuroblastoma. Eye (Lond) 2003; 17:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/19\">",
"      Maier W, Laubert A, Weinel P. Acute bilateral blindness in childhood caused by rhabdomyosarcoma and malignant lymphoma. J Laryngol Otol 1994; 108:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/20\">",
"      de F&aacute;tima Soares M, Braga FT, da Rocha AJ, Lederman HM. Optic nerve infiltration by acute lymphoblastic leukemia: MRI contribution. Pediatr Radiol 2005; 35:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/21\">",
"      Iqbal Y, Palkar V, Al-Sudairy R, et al. Papilledema, presenting as reversible loss of vision, in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 2005; 45:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/22\">",
"      G&uuml;ler E, Kutluk T, Akalan N, et al. Acute blindness as a presenting sign in childhood non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2003; 25:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/23\">",
"      Chaudhry IA, Shamsi FA, Al-Sharif A, et al. Optic nerve avulsion from door-handle trauma in children. Br J Ophthalmol 2006; 90:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/24\">",
"      Mankhambo LA, Makwana NV, Carrol ED, et al. Persistent visual loss as a complication of meningococcal meningitis. Pediatr Infect Dis J 2006; 25:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/25\">",
"      Hu WT, Leavitt JA, Moore EJ, Noseworthy JH. MRI findings of rapidly progressive ophthalmoplegia and blindness in mucormycosis. Neurology 2006; 66:E40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/26\">",
"      Lim SA, Siatkowski RM, Farris BK. Functional visual loss in adults and children patient characteristics, management, and outcomes. Ophthalmology 2005; 112:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/27\">",
"      Bangash IH, Worley G, Kandt RS. Hysterical conversion reactions mimicking neurological disease. Am J Dis Child 1988; 142:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/28\">",
"      Maloney MJ. Diagnosing hysterical conversion reactions in children. J Pediatr 1980; 97:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/29\">",
"      Leaverton DR, Rupp JW, Poff MG. Brief therapy for monocular hysterical blindness in childhood. Child Psychiatry Hum Dev 1977; 7:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/30\">",
"      Gospe SM Jr. Transient cortical blindness in an infant exposed to methamphetamine. Ann Emerg Med 1995; 26:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/31\">",
"      Shokunbi T, Agbeja A. Ocular complications of head injury in children. Childs Nerv Syst 1991; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     Olitsky SE, Hug D, Smith LP. Disorders of the eye. In: Nelson Textbook of Pediatrics, 18th, Kliegman RM, Behman RE, Jenson HB, Stanton BF.  (Eds), Saunders Elsevier, Philadelphia 2007. p.2569.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/33\">",
"      Sacchetti M, Lambiase A, Coassin M, et al. Toxic corneal ulcer: a frequent and sight-threatening disease. Eur J Ophthalmol 2009; 19:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/34\">",
"      Handler JA, Ghezzi KT. General ophthalmologic examination. Emerg Med Clin North Am 1995; 13:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/35\">",
"      Sit M, Levin AV. Direct ophthalmoscopy in pediatric emergency care. Pediatr Emerg Care 2001; 17:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/36\">",
"      Levin AV. Eye emergencies: acute management in the pediatric ambulatory care setting. Pediatr Emerg Care 1991; 7:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/37\">",
"      J&auml;ger HR. Loss of vision: imaging the visual pathways. Eur Radiol 2005; 15:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/38\">",
"      Davis PC, Hopkins KL. Imaging of the pediatric orbit and visual pathways: computed tomography and magnetic resonance imaging. Neuroimaging Clin N Am 1999; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/39\">",
"      Hamid RK, Newfield P. Pediatric eye emergencies. Anesthesiol Clin North America 2001; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/36/16970/abstract/40\">",
"      Rothermel H, Hedges TR 3rd, Steere AC. Optic neuropathy in children with Lyme disease. Pediatrics 2001; 108:477.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6441 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16970=[""].join("\n");
var outline_f16_36_16970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Visual media",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Open globe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chemical burn",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hyphema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Iritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Glaucoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lens abnormality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vitreous hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Retina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neuro-visual pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Functional visual loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Transient vision loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HISTORY AND PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monocular vision loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Binocular vision loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6441|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/13/24784\" title=\"algorithm 1A\">",
"      Monocular vision loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/38/33391\" title=\"algorithm 1B\">",
"      Binocular vision loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6441|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/57/17301\" title=\"figure 1\">",
"      Diagram of human eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/19/24887\" title=\"figure 2\">",
"      Localization VFD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/19/28989\" title=\"figure 3\">",
"      Morgan lens close up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/13/8405\" title=\"figure 4\">",
"      Hyphema grading table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/15/42239\" title=\"figure 5\">",
"      Afferent pupillary defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/51/821\" title=\"figure 6\">",
"      Orbital venous drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6441|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/10/8354\" title=\"picture 1\">",
"      Corneal lacerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/27/13745\" title=\"picture 2\">",
"      Intraocular foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/12/35023\" title=\"picture 3\">",
"      Corneal alkali burn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/57/26513\" title=\"picture 4\">",
"      Morgan lens insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/43/40638\" title=\"picture 5\">",
"      Morgan lens flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/54/21346\" title=\"picture 6\">",
"      Morgan lens removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/35/24112\" title=\"picture 7\">",
"      Hypopion 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/6/7279\" title=\"picture 8\">",
"      HSV keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/4/22592\" title=\"picture 9\">",
"      EKC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/43/19120\" title=\"picture 10A\">",
"      Hyphema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/59/32689\" title=\"picture 10B\">",
"      Hyphema 100 percent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/26/42415\" title=\"picture 11\">",
"      Hyphema grade IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/53/11103\" title=\"picture 12\">",
"      Lens trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/62/39919\" title=\"picture 13\">",
"      Dome shaped hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/28/38351\" title=\"picture 14\">",
"      Hyphema associated with endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/17/40222\" title=\"picture 15\">",
"      Traumatic retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/41/23187\" title=\"picture 16\">",
"      Fundus after CRAO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/37/42591\" title=\"picture 17\">",
"      Normal fundus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/53/33616\" title=\"picture 18\">",
"      Retinal vein occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/7/124\" title=\"picture 19\">",
"      Leukocoria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/53/18256\" title=\"picture 20A\">",
"      Early papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/23/11632\" title=\"picture 20B\">",
"      Fully developed papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31824\" title=\"picture 21\">",
"      Optic neuritis fundus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/22/29036\" title=\"table 1\">",
"      Causes of APVL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/28/16845\" title=\"table 2\">",
"      Open globe rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/59/28604\" title=\"table 3\">",
"      Chemicals associated with ocular burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/28/29133\" title=\"table 4\">",
"      Hyphema rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/16/23821\" title=\"table 5\">",
"      Classification glaucoma children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/12/6348\" title=\"table 6\">",
"      Visual behavior infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=related_link\">",
"      Approach to the adult with acute persistent visual loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/921?source=related_link\">",
"      Benign partial epilepsies of childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=related_link\">",
"      Central and branch retinal artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24520?source=related_link\">",
"      Craniopharyngioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=related_link\">",
"      Ectopia lentis (dislocated lens) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=related_link\">",
"      Epidemiology, diagnosis, and management of trachoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8456?source=related_link\">",
"      Eye disorders associated with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=related_link\">",
"      Gonococcal infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33992?source=related_link\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=related_link\">",
"      Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=related_link\">",
"      Optic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=related_link\">",
"      Optic pathway glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=related_link\">",
"      Orbital cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27751?source=related_link\">",
"      Preseptal cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=related_link\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4311?source=related_link\">",
"      Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38743?source=related_link\">",
"      Retinal vein occlusion: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=related_link\">",
"      Slit lamp examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17750?source=related_link\">",
"      Traumatic hyphema: Epidemiology, anatomy, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=related_link\">",
"      Treatment of exogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_36_16971="Effects pretransplant dialysis";
var content_f16_36_16971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effects of pre-transplant dialysis modality on outcomes early vs late after kidney transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Post-transplant period",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Relative risk (95 percent CI) PD:HD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Graft failure",
"       </td>",
"       <td class=\"subtitle2\">",
"        Death-censored graft failure",
"       </td>",
"       <td class=\"subtitle2\">",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        During the first 3 months",
"       </td>",
"       <td>",
"        1.23 (1.09-1.39)*",
"       </td>",
"       <td>",
"        1.33 (1.16-1.53)&bull;",
"       </td>",
"       <td>",
"        1.03 (0.81-1.30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beyond the first 3 months",
"       </td>",
"       <td>",
"        0.96 (0.87-1.05)",
"       </td>",
"       <td>",
"        1.02 (0.89-1.16)",
"       </td>",
"       <td>",
"        0.91 (0.80-1.04)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * P&lt;0.001.",
"     <br>",
"      &bull; P&lt;0.0001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Snyder, JJ, Kasiske, BL, Gilbertson, DT, Collins, AJ. A comparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int 2002; 62:1423. Copyright &copy; 2002 Blackwell Publishing.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16971=[""].join("\n");
var outline_f16_36_16971=null;
var title_f16_36_16972="Clues RD early childhood";
var content_f16_36_16972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clues to dyslexia in early childhood",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       The preschool years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trouble learning common nursery rhymes, such as \"Jack and Jill\" and \"Humpty Dumpty\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A lack of appreciation of rhymes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mispronounced words; persistent baby talk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Difficulty in learning (and remembering) names of letters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Failure to know the letters in his own name",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Kindergarten and first grade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Failure to understand that words come apart; for example, that",
"       <em>",
"        batboy",
"       </em>",
"       can be pulled apart into",
"       <em>",
"        bat",
"       </em>",
"       and",
"       <em>",
"        boy",
"       </em>",
"       , and, later on, that the word",
"       <em>",
"        bat",
"       </em>",
"       can be broken down still further and sounded out as: \"",
"       <em>",
"        b",
"       </em>",
"       \" \"",
"       <em>",
"        aaa",
"       </em>",
"       \" \"",
"       <em>",
"        t",
"       </em>",
"       \"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inability to learn to associate letters with sounds, such as being unable to connect the letter",
"       <em>",
"        b",
"       </em>",
"       with the \"",
"       <em>",
"        b",
"       </em>",
"       \" sound",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reading errors that show no connection to the sounds of the letters; for example, the word",
"       <em>",
"        big",
"       </em>",
"       is read as",
"       <em>",
"        goat",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The inability to read common one-syllable words or to sound out even the simplest of words such as",
"       <em>",
"        mat",
"       </em>",
"       ,",
"       <em>",
"        cat",
"       </em>",
"       ,",
"       <em>",
"        hop",
"       </em>",
"       ,",
"       <em>",
"        nap",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Complaints about how hard reading is, or running and hiding when it is time to read",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A history of reading problems in parents or siblings",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaywitz S. Overcoming Dyslexia: A New and Complete Science-Based Program for Reading Problems at Any Level. Copyright &copy; 2003 by Sally Shaywitz, M.D. Used with permission of Alfred A. Knopf, a division of Random House, Inc. For on-line information about other Random House, Inc. books and authors, see the Internet Web site at www.randomhouse.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16972=[""].join("\n");
var outline_f16_36_16972=null;
var title_f16_36_16973="Loop diuretic dose response";
var content_f16_36_16973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dose-response relationship between furosemide and sodium excretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between the rate of furosemide excretion and the increase in sodium excretion in normals (solid line) and patients with heart failure (HF; dashed line). A diuresis is not seen until a threshold rate of furosemide excretion is reached. Patients with HF show relative resistance at a given rate of diuretic excretion due to increased sodium reabsorption in other nephron segments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Brater DC, Day B, Burdette A, et al. Kidney Int 1984; 26:183.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16973=[""].join("\n");
var outline_f16_36_16973=null;
var title_f16_36_16974="Foot ankle circles";
var content_f16_36_16974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Foot ankle circles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Circle the foot at the ankle, moving the foot up and down by flexing and extending the ankle. Perform 20 rotations clockwise, then 20 rotations counterclockwise.&nbsp;The exercise is performed twice daily.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16974=[""].join("\n");
var outline_f16_36_16974=null;
var title_f16_36_16975="Diagnosis of gastroparesis";
var content_f16_36_16975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clinical and basic laboratory tests for gastroparesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 474px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TSH: thyrotropin; ANA: antinuclear antibody; CT: computed tomography; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_36_16975=[""].join("\n");
var outline_f16_36_16975=null;
